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resumo 
 
 
O presente relatório propõe-se a apresentar as atividades desenvolvidas 
durante um estágio curricular de 10 meses na Datamedica CRO Full Service. A 
estagiária encontrava-se a desenvolver atividades de monitorização de 
ensaios clínicos na empresa recetora pelo que este será o principal enfoque 
deste trabalho. Após 6 meses de estágio curricular, a Astellas Farma Lda 
subcontratou à Datamedica a estagiária em questão para desempenhar a 
função de CRA o que permitiu conhecer o mundo dos ensaios clínicos de duas 
diferentes perspetivas - a das grandes empresas da indústria farmacêutica e a 
das CROs (empresas subcontratadas pela indústria farmacêutica para 
desenvolver atividades específicas). 
 
Este trabalho tenta mostrar a visão obtida e os pontos de vista da estagiária 
enquanto monitora de ensaios clínicos das duas empresas. 
 
Para além da monitorização, foi possível desenvolver outras atividades em 
outros departamentos da Datamedica, nomeadamente realização de testes de 
legibilidade e atividades de medical writing que serão também apresentadas 
neste relatório. 
 
Este trabalho encontra-se dividido em dois principais capítulos sendo que o 
primeiro capítulo pretende situar a empresa de acolhimento na dinâmica da 
investigação clínica farmacêutica e dar a conhecer o estado da arte dos 
ensaios clínicos a nível europeu e nacional, com ênfase para a crise na 
investigação clínica em ambos os níveis. O segundo capítulo constitui a 
apresentação dos procedimentos que são seguidos em cada área de trabalho 
desenvolvida durante o período de estágio e a identificação de todas as 
atividades realizadas pela estagiária. O relatório termina com a discussão e 
conclusão de todo o trabalho desenvolvido e verificação dos objetivos de 
aprendizagem definidos no início do estágio. 
 
Todo o trabalho desenvolvido durante o estágio curricular e o contacto com os 
diversos profissionais envolvidos na área da investigação clínica foram 
fundamentais para a aquisição de competências sociais e intelectuais que 
contribuíram para o melhor desempenho da estagiária e a prepararam para o 
mundo profissional da indústria farmacêutica. 
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abstract 
 
This paper intends to present the activities developed during a 10-month 
internship at Datamedica Full Service CRO. The trainee was developing clinical 
trial monitoring activities at the host company, which will be the main focus of 
this report. After 6 months of internship, Astellas Farma Lda subcontracted the 
trainee from Datamedica to be one of their CRA’s, providing her with an 
opportunity to experience the world of clinical trials from two different 
perspectives - the major pharmaceutical companies and the CROs (companies 
subcontracted by the pharmaceutical industry to develop specific activities). 
  
This report tries to show the point of view of the trainee as clinical trial monitor 
of the two companies. 
Besides clinical trial monitoring it was possible to develop different activities 
from other Datamedica departments such as the realization of readability tests 
and medical writing activities that will also be presented in this report. 
This paper is divided in two main chapters, where the first chapter goal is to 
place the host company dynamics in the pharmaceutical clinical research 
environment and provide some knowledge about the clinical trials state of the 
art nationally and internationally, highlighting the clinical research crisis that is 
threatening the pharmaceutical world at both levels. The second chapter 
presents the procedures followed with the different activities performed divided 
by area of work and the identification/specification of each activity developed by 
the trainee. The report ends with a discussion and conclusion about the work 
developed and the verification of the learning outcomes defined at the 
beginning of the internship. 
 
The work developed during this curricular internship and the contact network 
developed through the contact with a variety of professionals involved in the 
clinical research area were essential in the acquisition of social and intellectual 
skills that contributed to the best performance of the trainee during the 
internship and prepared her to the professional work environment of the 
pharmaceutical industry. 
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Introduction 
The present work consists of an internship report developed under the scope of the second year of 
the Master Degree in Pharmaceutical Biomedicine at University of Aveiro.  
From September 2011 to March 2012 it was developed a curricular internship (also called on the 
job training) at Datamedica CRO Full Service, in the Clinical Investigation Department, as a 
Clinical Research Associate (CRA). The area of expertise in which the internship was focused, was 
chosen by the trainee and consists on the area she wants to develop a future career in. From March 
to the present time the trainee was outsourced from Datamedica to a Pharmaceutical Industry 
Company - Astellas Farma Lda where she has been working as a CRA as well. Therefore, this 
report will be focused on a 10-month period encompassing the internship period (of 6 months) at 
Datamedica and 4 months at Astellas Farma.  
As a result of this experience this report is being elaborated with the primary aim to describe the 
trainee’s experience at Datamedica CRO Full Service. An insight will also be given about the 
trainee’s job at Astellas. In addition, the present report will demonstrate the new skills, experience 
and knowledge acquired. 
Through the curricular internship the trainee intended to achieve the following learning outcomes: 
1. Be introduced to the professional world, by being part of a company staff that allows to 
perform and specialize in the area chosen to develop a professional career - clinical trials 
monitoring; 
2. Gather know how about how the clinical trials business works and the responsibilities that 
arise when entering the professional world; 
3. Consolidation and application of the theoretical knowledge acquired during the Masters’ 
and the Biomedical Sciences degree; 
4. Acquire in depth knowledge related to clinical trial monitoring and develop specific skills 
required to develop the CRA work; 
5. Establish a professional contact network by working in collaboration with other health 
professionals, such as physicians, pharmacists, other CRA and CRM, among others, whose 
activities are frequently connected with the CRA work and the conduction of clinical trials; 
6. Develop important team work skills and good interpersonal relationships among the 
companies colleagues and line managers and other professionals that may cross path with 
the trainee; 
7. Get acquainted with the host company functional dynamics; 
8. Accomplish all the proposed tasks in a precise, careful and successful way; 
9. Resolve situations in the face of adversities; 
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10. Develop activities not related to clinical trial monitoring but part of the scope of activity of 
the host company. 
These training learning outcomes were defined by the trainee at the beginning of the internship 
experience. The achievement of these learning outcomes will be discussed in a later chapter.  
This report is divided in 4 main chapters. 
The first chapter starts with a description of the host company where the internship took part and 
the company where the trainee got her first job. This section is followed by a clarification of how 
the pharmaceutical business works - a description of its dynamics - and since the trainee has been 
developing activities concerning clinical trials, the applied legislation and regulatory authorities 
will be presented. To conclude this chapter, a small glimpse about the European and Portuguese 
clinical trials state of the art will be introduced. 
The second chapter of this report consists of the methods and results of the internship, that is, a 
description of how the trainee performed her activities at Datamedica and specifically which 
activities where performed. 
The third chapter focuses on a discussion about the trainee’s activities at Datamedica and Astellas 
where the problems and challenges the trainee went through are evidenced as well as the positive 
aspects of each activity. Along this chapter the trainee performs an assessment about the 
achievement of the learning outcomes. 
Lastly, the conclusion alludes to the impact these 10 months had in the trainee’s growth as a 
professional worker in the pharmaceutical industry world and her future. 
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1 - The Current Clinical Research Environment  
This chapter has as main purpose to provide an overview about the clinical research environment at 
which the trainee started her on the job training. To achieve this goal, this chapter is divided in 5 
sections, starting with the description of the trainee’s host company to show its role in clinical 
research followed by the introduction of the current legislation and authorities regarding clinical 
trials and ending with the state of the art of clinical trials in Europe and particularly in Portugal. 
 
1.1 - Host Company Overview 
Datamedica is a CRO (Clinical Research Organization) created in 1996 with the goal of creating a 
multidisciplinary research company that could support the pharmaceutical industry, universities 
and other companies dedicated to healthcare research. For 16 years this company has been in the 
national territory and since its beginning it has had several leaders that gave different purposes to 
the company. At first it only focused on Biostatistical services but progressively expanded (Figure 
1). The environment the trainee experience focused mainly in clinical research, specially 
conducting CT (Clinical Trials). In more technical words Datamedica is a Full Service CRO whose 
services encompass “all phases of the Clinical Trial cycle, including study planning, selection of 
study centers and investigators, centralized randomization, study monitoring, back-office support 
and total quality management”.(1)  
 
 Figure 1 - Datamedica’s evolution through the years (Adapted from ref. 1) 
 
This is a small company made of only 10 people in house, which made personal interactions with 
everyone in the company easier to the trainee but working in a small company is different from 
working in bigger companies because in those companies there is people for each task that needs to 
be performed. In Datamedica’s case, even though everyone has an area of expertise, the trainee 
needed a multi - task ability, as employees are required to perform all necessary tasks, even if it is 
1996 - 
Biostatistics 
only 
1997 - Adds 
CT 
Monitoring 
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Epidemiology 
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1999 - 
Medical 
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2000-2001 
Pharmaco-
economics and 
pharmaco-
epidemiology 
emerges at the 
company 
Today CRO 
FULL 
Service 
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out of their specialization.(2) In the trainee’s opinion this situation was considered an opportunity 
because it allowed her to get to know other areas of expertise available in the pharmaceutical 
industry and experience them but on the other hand it required to have very good organizational 
skills, to know how to prioritize the work activities and to be 100% committed. 
The trainee thought the company facilities were very welcoming and adapted to the collaborators 
needs. Everyone had their own cubicle equipped with a laptop, phone and other 
necessary/specialized equipment and in addition there was a common space with an enormous desk 
where, when necessary, the team members can work together. Since the trainee was working as a 
CRA trainee and due to the frequent need to be in the different clinical trial sites, the company 
provided a car to the trainee. 
Due to its size and high cooperation between its collaborators, there is not a clear limitation of the 
different departments/units. The trainee was able to identify the department/units of Datamedica 
with the assistance of Datamedica colleagues and created figure 2. It is important to notice that 
some of these departments are made up of only one person: 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Datamedica Organizational Chart - The areas in red represent the department units at 
which the trainee performed the internship activities (Adapted from ref. 1) 
 
Datamedica is organized in three different departments: the Financial and Administrative 
department, the Commercial department and the Clinical Investigation department. The clinical 
investigation department represents the largest part of Datamedica’s line of work focused on all 
clinical trials related activities (from clinical trials design, bibliographic research to support the 
clinical trial, development or revision of clinical trials’ protocol, informed consent and case report 
form, clinical trial monitoring, statistical analysis and study results publication).  
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Most of the staff main role in the company is related to Project management, Clinical Research 
Manager (CRM) and Clinical Research Associate (CRA). The Clinical Investigation unit was 
where the trainee developed more skills as CRA, by monitoring clinical trials, as pointed out in red 
in figure 2. 
The Data management and Biostatical unit develops one of Datamedica’s most important activities. 
This unit is responsible for the performance of the statistical analysis of CT, calculation of the 
sample size for the CT performed at Datamedica, development of statistical reports, among other 
statistical analysis.  
Besides the tasks developed as CRA, the trainee also took part in some activities related to the 
regulatory affairs unit, performing readability tests. It also assisted in some medical writing work, 
such as the design of Case Report Forms, clinical trials informed consent, among other tasks, which 
is a recent expansion of the line of work of Datamedica. The trainee’s participation in these units 
was not as frequent as in the clinical investigation.  
The activities developed by the trainee at Datamedica will be described with more detail in chapter 
2. 
In order to help to successfully perform the core of the CT monitoring, the trainee noticed that there 
were in place several in-house developed information technology systems: COATI (Control, 
Assessment and Tracking of Therapeutic Investigations), PANDA (Data Analysis Package) and 
DART (Data Analysis and Reporting Tool) (Figure 3).(1) These are expert databases of great 
assistance in handling CT. There was only a small setback on the use of these databases - they were 
developed a few years ago, and because Datamedica is frequently updating its informatics system 
and the employees laptops, some of the more recent software’s did not run these programs which 
means they only worked in the oldest computer at the company that is operating at a low speed.   
 
 
Figure 3 - Datamedica’s IT systems (Reproduced from ref. 1) 
 
•  PANDA is a database 
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• DART is an intelligent data 
analysis tool that generates 
automatic statistical analyses of 
clinical trials under user 
supervision after receiving pre-
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12 
As a CRO in Portugal, Datamedica has a number of competitors and to keep running it needs to 
find more clients. In the trainee’s opinion this is a difficult task for Datamedica, due to its size and 
the current crisis situation. However, Datamedica has proven the trainee wrong by welcoming a 
new general director – Luís Fatela - that explored his professional connections and allowed new 
people to become aware of Datamedica, and by creating an extension of the company in Angola. 
These two actions seek the opportunity of growth both in the national and international markets. 
This was a change in the history of Datamedica that the trainee witnessed and occurred in just a 
couple of months (see end of chapter 3).  
In March 2012 the trainee was outsourced to Astellas Farma, Lda, which has a completely different 
dynamic when compared to Datamedica. For starters, Astellas is an affiliate of an international 
pharmaceutical industry company with Astellas Pharma Europe, Ltd (APEL) as the main European 
House. It is one of the 20 biggest pharmaceutical companies in the world. This is a company that, 
as it is known today, only exists for 7 years when Yamanouchi and Fujisawa (two major Japanese 
pharmaceutical companies) fused. In Portugal the roots of Astellas Farma were created in 1967.(2) 
This company has 21 affiliates throughout Europe and South Africa which by itself shows its size 
and influence.(2)  
This outsourcing situation was only possible because Astellas subcontracted Datamedica, 
requesting one of its CRAs. 
On the opposite from Datamedica, Astellas Portugal is composed of approximately 70 people, 
distributed by the various departments. The biggest department at Astellas is marketing and sales, 
due to the fact this company’s main goal is to promote and sell its products, but the Medical & 
Regulatory Affairs department is also one of the most important departments where regulatory 
affairs, medical advice, pharmacovigilance and clinical investigation are focused. The different 
departments’ limits are very clear and everyone has its work activity very well defined. Some 
people never communicate with each other because their paths don’t cross, so it was difficult for 
the trainee to keep track on the people working there and to get to know everyone. To help with 
this situation, Astellas once or twice a year organizes annual meetings with team building activities 
so that everyone gets to know everyone and to promote team work, effort and interpersonal 
relationships. 
Similarly to Datamedica, Astellas is highly equipped and their collaborators are highly specialized. 
Each collaborator has to go through training on their Standard Operating Procedures (SOP) and 
software, and each one has its own laptop, working station, intranet service, telephone, mobile 
phone and car. The company also has a department specialized in solving the informatics problems, 
and a human resources department. 
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The trainee was part of the Medical & Regulatory Affairs Department, composed of 10 people, and 
as in Datamedica she was developing CRA activities. The company has highly regulated activities, 
with department meetings every two weeks in order to keep track of the collaborators work, needs, 
problems and successes. In addition every collaborator is frequently in contact with the European 
main house through teleconferences, which was something that did not happen at Datamedica. 
Astellas Pharma Europe, Ltd, five main therapeutic areas are: Transplantation, Urology, 
Dermatology, Anti-infectives and Pain. It is in these areas that this company has been developing 
its products and has focused its clinical trials.(2) The trainee as an Astellas collaborator had the 
chance to work with the Urology and Pain therapeutic areas. 
These two companies are completely different, especially in size, which allowed the trainee to see 
how the size of the company influences their work dynamics and how each company performs their 
activities (see end of chapter 3). 
 
1.2 - Clinical Research Stakeholders and Their Role 
Datamedica and Astellas are two types of companies that belong to two different levels in the 
pharmaceutical industry but share the same main focus: improve patient’s healthcare through 
different extents and activities. They can be called as stakeholders of this industry, and it can be 
said the trainee was part of two different stakeholders for the last 10 months. Figure 4 emphasizes 
the main stakeholders in investigational research that revolves around patients and the 
improvement of its health by providing new medicinal products/devices/procedures and other 
solutions and each will be discussed in the paragraphs below.  
 
Figure 4 - The different stakeholders with impact on patient healthcare – The areas in red 
represent the stakeholders of the pharmaceutical industry that the trainee was part of  
 
When talking about big pharma companies it is being referred companies such as Roche, 
GlaxoSmithKline, Astrazeneca and Astellas Pharma among others.(3-5) 
Patient 
Healthcare 
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These are companies that have resources and capabilities to discover, develop, manufacture and 
market innovative medicines for major diseases all in the same company. These companies have 
affiliates around the world and each affiliate most of the times only has one or two of these 
functions/activities and only the company headquarters gather all these functions. 
They all have in common their mission/goal: the improvement of people’s life through the 
development and introduction of innovative medicines that allow them to live longer, healthier and 
feel better. To do that, they focus on research and development, by developing the new innovative 
medicines from the discovery phase to the confirmatory phase (preclinical and clinical 
development) and commercialization. The difference between them is that each company has 
specific therapeutic areas so that all together they can provide more innovative medicines that 
respond to most of the worldwide diseases. For example Astrazeneca, defined cancer, infectious, 
cardiovascular, respiratory and gastrointestinal diseases as their focus and more than half of the 
Roche’s projects focus on oncology, inflammation/immunology, virology, neuroscience and 
metabolic diseases.(3, 5)  
In the last decades, instead of the integrated model mentioned above, where the services needed to 
bring new and innovative medicines to the market were incorporated in the company and their 
affiliates, it was put in place a new concept that emerged in the 1970’s – service outsourcing that 
means “to obtain (goods or a service) from an outside or foreign supplier”. This way 
pharmaceutical industries acquire some services from companies that are specialized in specific 
services (see figure 5) - Contract Research Organizations (CROs). 
 
Figure 5 - Representation of the new pharma business model - Outsourcing (Adapted from 
ref. 11) 
 
CROs started out to be a “simple fee - for service business”.(6) They allowed to “keep off the 
burdens and overheads of process management so big pharma can focus on the medical, scientific, 
and regulatory aspects of drug development”.(7) 
The globalization and the economical crisis that has been felt over the last couple of years has been 
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a major booster on the growth and impact of CROs since they help to reduce the pressure to 
produce and the costs and time from the pharmaceutical companies. The number of connections 
between developers and CROs has increased at an elevated rate.(7) 
 In addition, the range of services contracted has also increased. First, the main services outsourced 
were mostly pre-clinical and drug discovery services and other single projects (figure 6), however, 
big pharma are now looking for CROs that can supply entire development programs – “there's been 
a shift to more strategic outsourcing where CROs are no longer mere service providers, but full 
service collaborators (full service CRO)”.(7) 
 
Table 1 - Examples of the different CROs types (8-11) 
CRO Type Service Provided Example 
 
Full Service CRO  
•A CRO that provides all the services 
needed in a clinical research program 
•One outsourcing process, negotiation 
and possibly one contract 
 
 
Datamedica 
 
 
 
Niche CRO  
•A CRO that specializes in a particular 
activity/task in the clinical research 
program 
•The sponsor has control over 
outsourcing process and service provider 
selection 
 
 
MEDSOURCE 
 
 
 
Academic CRO  
•”Academic Researchers are the opinion 
leaders in a disease or experts in a given 
methodology” (10) 
•”Some academic research centers have 
determined to offer contract services 
beyond the traditional sponsor-
investigator collaboration” (10) 
 
 
University of Surrey - 
Surrey Clinical 
Research Center 
 
  
Some experts say CROs are the future of the world of pharmaceuticals. Lately, the major 
pharmaceutical companies are cutting their personnel as a result of the high difficulties brought by 
the economic crisis, and these ex-pharmaceutical industries employees find a new job in CROs. 
The technical skills needed to work in a CRO largely overlap with the ones required in the 
pharmaceutical industry. This situation is showing how CROs can grow in times like this by 
benefiting from the experienced personnel and their professional contacts network. This is only bad 
for early career professionals, such as the trainee, since they have to compete and if they’re lucky 
they will have the chance to learn with these highly experienced professionals.(12) Another proof 
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of CRO’s growth is the current expansion of more Portuguese CRO’s to developing countries such 
as Brazil, Angola, Argentina, Chile, among others. As previously mentioned Datamedica has 
opened the doors to the international market through its expansion to Angola and it is not the only 
CRO doing this.  
 
Besides Big Pharma and CROs there are also academic institutions, laboratories and SME’s 
involved in clinical research and focused on the improvement of the global healthcare. 
The trainee identified two main roles of academic institutions in clinical research. The first is 
related to the fact that universities with their research centers provide breakthroughs and 
innovations (new molecules, genes and biomolecules, disease-specific variables, risk factors, or 
routes, new innovative technology, etc) to the pharmaceutical industry that can be used in the 
development of innovative drugs, mainly in the early stage research and clinical trials. However, a 
gap exists between academia and the pharmaceutical industry, as collaboration between these two 
stakeholders has not been promoted, especially due to intellectual property and technology transfer 
issues. But, this is currently being fixed (see section 1.4).(13, 14)The second role of academia is the 
provision of the right training and education to the current and future professionals. There have 
been some changes in the way universities provide training and education so that future 
professionals are “trained in next-generation techniques, applications, project management, 
collaboration models, and regulatory science”.(14)  
Small and Medium Enterprises (SME) also provide services in clinical research - they support 
clinical research and focus on improving patient healthcare. SME “are independent companies with 
one or more minority partnerships and with fewer than 50 persons and whose annual turnover or 
annual balance sheet total does not exceed 10 million euro”.(15) SME are important for the 
economy and improve employment but its major problem is in obtaining capital or credit, 
particularly in the early start-up phase which require access to new technologies or innovation.(15) 
SME may be subcontracted by pharmaceutical companies or by CROs as they can be specialized in 
different fields or even in more than one. Figure 6 provides an overview of SME registered in EMA 
and their specialization. 
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Figure 6 - The phase of development in which SMEs focus (Reproduced from ref. 16) 
 
Finally there are the laboratories that support clinical research. Laboratories can also be 
subcontracted by pharmaceutical companies to perform some clinical research activities. Most 
laboratories that support clinical research are part of the discovery phase of clinical research. In 
addition there are a number of laboratories that support clinical trials - the so-called central 
laboratories where blood samples, urine samples and other type of analysis required by specific 
clinical trials are sent and processed so that the same parameters are applied, which is important in 
international clinical trials. 
 
These are just some of the main stakeholders in the clinical research environment. The most 
important message to retain is that they are all interconnected and support each other, especially 
nowadays. 
 
1.3 - Clinical Trials Regulation and Regulatory Authorities 
 At this stage, it is important to properly define clinical/investigational research.  
For the purpose of this report, investigational research will mainly correspond to clinical trials, 
since it has been the main area of focus of the trainee for the last year. The present section is going 
to introduce clinical trials as well as the regulations and regulatory authorities regarding them.  
Clinical trials are defined in Directive 2001/20/EC of April 4 as “any investigation in human 
subjects intended to discover or verify the clinical, pharmacological and/or other 
pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify 
any adverse reactions to one or more investigational medicinal product(s) and/or to study 
absorption, distribution, metabolism and excretion of one or more investigational medicinal 
product(s) with the object of ascertaining its (their) safety and/or efficacy”.(17) This definition 
shows why clinical trials are so prone to a highly regulated environment: the fact that they involve 
human subjects whose safety and rights must always be protected. Consequently, there are a 
18 
number of laws, guidelines and directives that instruct and advise how to proceed with clinical 
trials and the subjects involved and several regulatory authorities that are responsible to regulate 
the way clinical trials should be conducted.  
The first that is presented in this report is the European Commission that has an important role 
when alluding to the requirements to conduct clinical trials in the European Union (EU). It is 
responsible for publishing EUDRALEX – “The rules governing medicinal products in the 
European Union” which contains all the European legislation applied to the pharmaceutical sector. 
Volume 10 holds the guidelines applied to clinical trials and has published the main directives
1
 
approved in the European Parliament.(19, 20) These are: 
 Commission Directive 2001/20/EC of “April 4 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the implementation of 
good clinical practice in the conduct of clinical trials on medicinal products for human use”;(19) 
 Commission Directive 2005/28/EC of April 8 2005 which further concretizes the previous 
directive by “laying down principles and detailed guidelines for good clinical practice as regards 
investigational medicinal products for human use, as well as the requirements for authorization of 
the manufacturing or importation of such products";(19)  
 Commission Directive 2003/94/EC of October 8 2003 which lays down “the principles and 
guidelines of good manufacturing practice in respect of medicinal products for human use and 
investigational medicinal products for human use”;(19) 
The most important of these 3 directives is Directive 2001/20/EC, which is usually called as “The 
Clinical Trials Directive”. In Portugal, Lei n. º 46/2004, de 19 de Agosto (Law nº 46/2004 of 
August 19) is the national transposition of directive 2001/20/EC.(21) 
Besides the European Commission there are other regulatory authorities that regulate clinical trials 
both in Europe and Portugal. The European Medicines Agency (EMA), International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) and INFARMED - Autoridade Nacional do Medicamentos e Produtos de Saúde I.P. 
(National Authority of Medicines and Health Products) are some of them and are going to be 
further characterized below. 
 
European Medicines Agency (EMA) : 
EMA is a decentralized body of the European Union and its main goal is to protect and promote 
human and animal health. It is capable of accomplishing its goal by supervising and evaluating the 
                                                 
1 A directive is a legislative act of the EU that lays down the objectives to be achieved by the Member States 
but it does not define the means to achieve them. The directives recipients may be one or several member 
states and the national authorities have to adapt their laws to meet the directive goals. (18)  
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medicines for human and animal use. Its role spans from constant monitoring of the safety of 
medicines through pharmacovigilance to providing scientific advice and publishing guidelines
2
 on 
quality, safety and efficacy testing requirements that are available for whoever wants to consult 
them and are additional to the information provided in the EUDRALEX.(22) 
 
International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) 
Before 1990, every country that wanted to market new compounds would have its rules and 
regulations about what was required to market a new drug. This meant that, to market a compound 
at an international level it would be necessary to apply the specific procedures of each country 
where the product would be marketed, which is time consuming and expensive. ICH was the 
solution to this problem. It is a conference that took place for the first time in April 1990 in 
Brussels at which the regulatory authorities, industry associations and other representatives of 
Europe, Japan and the US defined that the interpretation and application of procedures and 
requirements of safety, quality and efficacy (the three topics based for approving and authorizing 
new medicinal products) should be harmonized to allow access of new drugs in these three regions 
more quickly and with simpler procedures (“reducing or obviating duplication of testing carried 
out during the research and development of new human medicines”).(23)  
During the last few years, ICH has had an important role mainly reflected on the number of 
guidelines developed focused on the three topics mentioned above. In addition it has tried to 
expand its activities and function to other non-ICH regions, to expand the harmonized procedures. 
 
INFARMED 
The Portuguese national competent authority was created with the intent to “regulate and supervise 
the areas of medicinal products for human use, medical devices and cosmetics and body care, 
according to the highest standards of public health protection, and to ensure health professionals 
and citizens access to quality, effective and safe medicines, medical devices, cosmetics and hygiene 
products”.(24) 
                                                 
2
 A guideline is a communitarian document mentioned in the legislation as indicated to fulfill a legal 
obligation in the pharmaceutical legislation or is considered a support document for applicants or marketing 
authorization holders and/or stakeholders so that they can appropriate fulfill the legal obligations contained in 
the pharmaceutical legislation. They reflect the most recent and harmonized approach of the scientific 
knowledge. Most guidelines do not have legal application but they are considered the harmonized position of 
the Community, which is followed by the pharmaceutical industry stakeholders. Different approaches than 
the ones defined in the guidelines can be followed if properly justified. 
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 In order to accomplish its aim, this national competent authority needs to regulate and supervise 
clinical trials, a task that is performed by its unit Direcção de Avaliação de Medicamentos (DAM-
Drug Evaluation Board) and its subunit Unidade de Ensaios Clinicos (UEC - Clinical Trials Unit). 
It is this specific unit that is responsible for providing all the necessary activities related to the 
authorization of CT on a medicinal product for human use and substantial amendments to CT 
already authorized. Also, it guarantees the continuous follow up of CT according to the 
authorization terms.(24) The other business units with activities related to clinical trials are: 
 Direcção de Gestão de Risco de Medicamentos (Risk Management Board of Medicinal 
Products) responsible for monitoring the safety of medicinal products for humans (collecting, 
register and assessing adverse reactions from clinical trials, periodic safety reports, etc);(24) 
 Direcção de Inspecção e Licenciamento (Licensing and Inspection Board) which is the unit 
responsible for good clinical practices inspections related to clinical trials through the subunit of 
Unidade de Inspecção (Inspection Unit).(24) 
 
In Portugal there are two other independent entities that are important to consider when in it comes 
to clinical trials. These are Comissão de Ética para a Investigação Clínica (CEIC - Clinical 
Investigation Ethics Committee) and Comissão Nacional de Protecção de Dados (CNPD - National 
Data Protection Committee), which will be explored below. 
 
CEIC 
CEIC is the national ethics committee for clinical research and it is an independent organization 
responsible for assuring the rights, safety and well being of the participants in clinical trials. This is 
accomplished through an assessment of the clinical trial and the procedures to which the 
participants will be subjected. Before the clinical trial starts, the sponsor of the clinical trial or 
another applicant selected by the sponsor must submit all the clinical trial elements (clinical trial 
protocol, the informed consent, insurance, the amount and terms of remuneration of researchers and 
participants, the investigational team CV’s, etc) to CEIC in other to get its ethical opinion.(25) 
During the clinical trial CEIC closely monitors the trial and must be frequently informed about 
amendments to the trial that directly relate to the clinical trial subjects. 
 
CNPD 
CNPD is a public institution responsible for controlling and verifying the processing of personal 
data in order to make sure it is respecting human rights and the constitutional law.(26) 
In terms of clinical trials CNPD is responsible for giving an opinion and authorize the personal data 
processing. The sponsor of the clinical trial must inform CNPD that it is going to be performed a 
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clinical trial that encompasses personal data processing and with the notification of CNPD it must 
be provided the documents that relate to the data being processed. (26) 
 
Since there are a lot of regulatory procedures of different regulatory authorities to be followed when 
conducting CT, in the first weeks of the internship, the trainee was subjected to a training period 
where the most important legislation related to clinical trials had to be read and understood. The 
trainee had to go through all these organizations websites to get familiarized with their content and 
read the most updated legislation and guidelines. The following are the most important: 
 Commission Directive 2001/20/EC  
 Commission Directive 2005/28/EC  
 Commission Directive 2003/94/EC of October 8 2003  
 Deliberation Nº 333 / 2007 of CNPD Sobre a protecção de dados pessoais nos ensaios 
clínicos com medicamentos de uso humano (About the personal data protection in clinical trials 
with medicinal products for human use) 
 Law no 46/2004: transposition of Directive 2001/20/EC (11); 
 Decree-Law no 102/2007: transposition of Directive 2005/28/EC (12); 
 Law no 67/ 98 – Lei da Protecção de Dados Pessoais 
 ICH Efficacy guideline E6 Good Clinical Practice 
 ICH Efficacy guideline E8 General considerations for clinical trials 
Also, the trainee had to read through CEIC, INFARMED and CNPD considerations about the 
requirements to get an authorization to perform a clinical trial, to get a favorable opinion of the 
ethics committee and to notify CNPD when sensible/personal data is going to be assessed. 
 
1.4 - Current State of the R&D Process in Europe 
After explaining the definition of clinical trials and the main regulations and regulatory authorities 
and, before introducing the Portuguese environment concerning clinical trials, a brief glimpse 
regarding the European state of the art of R&D (Research & Development) in which clinical trials 
are inserted is of great significance to understand the importance R&D has for the European 
economics. 
In the last decades the R&D process, which culminates in the commercialization of a new drug, has 
been a logical and sequential process. This process starts with research activities based on a 
screening process of thousands of compounds to find a compound, called “the lead compound”, 
that shows potential to cure or relieve symptoms of a specific disease. This compound will be the 
one that goes through the Development process, which is the second part of the R&D process.(27) 
The current drug development process has been mainly based in trials. First there are the non-
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clinical trials that will support the clinical trials of a given scope and duration and give information 
about the safety of a new pharmaceutical through an animal safety and efficacy evaluation.(28) 
With the information acquired from the nonclinical trials, it is possible to start the first 
administration of the pharmaceutical medicine on humans (First-in-Human clinical trials). The 
early clinical trials are smaller and determine the initial safety and tolerability of the doses chosen 
for the new drug. These trials support the latter clinical trials, which are larger and provide 
confirmatory information about the efficacy of the new drug in the target disease and populations. 
The information acquired with phase I clinical trials frequently allow modifying the development 
strategy.(29) Clinical trials are characterized in four temporal phases (Phase I to Phase IV) but this 
classification has proved to be inaccurate since “one type of clinical trial may occur in several 
phases” as it can be seen in figure 7. Through the grey circles in figure 7 it is shown which type of 
trials are more frequently conducted in each phase and shows that the characterization through 
objectives is more accurate.(29) However, the trainee verified that the most frequently used 
terminology is still the four temporal phases.  
 
Figure 7 - Clinical Trials Classification (Reproduced from ref. 29) 
 
This R&D process has been used for decades and has contributed to the increase in the number of 
new drugs that have been marketed. This increase in development of new drugs has coincided with 
the biopharmaceutical industry steadily growth in Europe and its acknowledgment as an important 
contribution to the European Health and economy.(30) 
However, nowadays, this R&D process is currently presenting some setbacks in Europe. It has 
been verified that in the last 10-15 years there has been a decline in the R&D productivity,(31) 
mainly due to the fact that the number of new drugs introduced each year has not kept pace with 
the R&D costs. As it is possible to see in figure 8, even though the costs to bring a new chemical 
entity has exponentially grown, the number of New Chemical Entities (NCE) has declined 
substantially.(31) With the current R&D process, it would take, on the year 2000, an average of 
618 Million Euros (802 Million USD) to bring a new drug to the market and the trend has been an 
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increase in this value. 
 
Figure 8 - Number of new chemical entities that reached the market vs. R&D expenditure 
(Reproduced from ref. 31) 
 
Also, there is the fact that quite often the drug, that took 10-12 years to develop, when marketed 
lacks efficacy and the pharmaceutical companies see all their efforts, money and resources thrown 
away. This requires a new R&D process that allows to find out which of the lead compounds and 
drugs aren’t going to work when applied to a broader population so that money and time can be 
saved.(11) 
This is the major bottleneck but there are several other characteristics of the R&D process that 
contribute to this problem and compromise the biopharmaceutical R&D market such as the time it 
takes to bring a new drug to the market (approximately 12 years). The clinical development phases 
are the ones where most of the income in the pharmaceutical development is spent, which allows 
concluding that longer clinical development times drive higher costs and investment in drug 
candidates. This R&D process has also been associated with elevated attrition rates, which is the 
failure of a NCE that starts phase I clinical trials to achieve market commercialization. Only 8% of 
new drugs get approved, the remaining ones fail to achieve approval due to lack of efficacy, 
clinical safety concerns and toxicological findings.(31)  
In addition, some European competitors are currently presenting more attractive market conditions 
which is causing a relocation of the R&D investments by biopharmaceutical companies to the US 
and Asia, bringing serious consequences to the European economy and health.“In 1990, major 
European research-based companies thus spent 73% of their worldwide R&D expenditure on the 
EU territory, while the figure was only 59% in 1999”.(30)  
The acknowledgment of this impact has worked as a “Wake up call” to Europe that decided to find 
a solution to this problem through the collaboration between the stakeholders in the 
biopharmaceutical business and the creation of the Innovative Medicines Initiative (IMI).(30) IMI’s 
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mission “is to contribute to creating biomedical research and development (R&D) leadership for 
Europe to benefit patients and society”.(32) “It aims to build and exploit new scientific knowledge 
and technologies through pan-European Public-Private Collaborations to better enable the 
discovery and development of new medicines. IMI will make the process of developing new 
medicines more efficient by conducting research to apply new technologies to drug discovery and 
development”.(33) This is done through the consensus, participation and contribution of resources, 
expertise and know-how of the main stakeholders in the pharmaceutical industry, which are: 
academia, R&D pharmaceutical companies, small and medium enterprises, regulatory authorities 
and patient organizations.(33) 
The areas and activities to be covered by IMI projects are defined in the Strategic Agenda. The first 
Strategic Research Agenda (SRA) was made in 2008 but was revised in 2011 to address the new 
challenges and gaps. The first SRA defined four pillars that would be the focus of the IMI activity. 
The aim was to improve prediction of safety evaluation (early indications of safety problems) and 
efficacy evaluation (early indication of efficacy by using biomarkers), bridge knowledge 
management gaps (collaboration to break information barriers) and educational gaps (across 
preclinical and clinical research and between disciplines.(31) These four pillars were expanded in 
2011 to 7 areas of research interest (due to the recent changes in the health systems, pharmaceutical 
industry and the progress of new science and technology) represented in figure 9.(32) 
 
Figure 9 - IMI 7 areas of research interest (Reproduced from ref. 32) 
 
IMI is needed in the European biopharmaceutical industry market but its results will be more 
relevant on the medium to long term. One thing is for sure - it has been promoting the collaboration 
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of the variety of stakeholders in this business. 
Another different approach that has been gaining supporters is the new R&D process based in 
personalized medicine. Personalized Medicine means having the right treatment, for the right 
patient at the right time. This is now being pursued thanks to the major developments in 
pharmacogenomics and molecular biology that have allowed the identification of the genes 
responsible for a specific disease characteristic, the response of a person to a given therapy, 
prediction of a disease outcome, the potential to develop adverse drug events, identifying patients 
for increased success in CT, etc. This is going to allow giving a specific patient the most suitable 
drug after identifying his particular type of genetic scheme. Diagnostic methods based on 
pharmacogenomics are extremely important to achieve personalized medicine. (34, 35) To achieve 
personalized medicine it is required a high collaboration between basic research (universities), drug 
developers (big pharma), regulatory authorities and caretakers.(36) 
Basically, the one-size-fit all paradigm is being replaced by a new one that meets individual needs.  
If it is taken into consideration the trainee’s experience at Astellas Farma, a big pharma company, it 
is her opinion that the change from the current paradigm will occur slowly and at least in the next 
couple of years clinical research will still be based on clinical trials. At least, Astellas is planning 
for the near future a reasonable number of clinical trials. The main driver for change will be the 
biomarkers, which are being introduced in the clinical trials for patient recruitment. 
 
1.5 - Performing Clinical Trials in Portugal 
In Portugal, R&D is also an important area of investment. The Portuguese government recognized 
the pharmaceutical industry sector as a key strategic sector important to the Portuguese economy 
and growth. Therefore, in the last couple of years R&D has been promoted and as a result R&D 
and health care spending has increased and clinical research has been strongly stimulated which has 
been contributing to make Portugal an important pharmaceutical market.(37, 38) 
In Portugal there are approximately 130 pharmaceutical companies operating where most of these 
are multinational companies promoting clinical research.(37) 
On the one hand, Portugal has a number of hospitals and universities in major cities (Porto, Lisbon, 
Coimbra, etc) with experienced personnel (most hospital investigators have conducted clinical 
trials) to perform and assist clinical trials. It also has a good reputation in what comes to English 
knowledge of their professionals (either in the pharmaceutical sector or other), which is quite 
important in this field. Besides the human resources, the hospitals infrastructures are also adequate 
to the performance of clinical trials (with the availability of facilities such as pharmacy, ethical 
committee, monitoring room, etc). One important characteristic that has been noticed is the high 
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patient compliance in clinical trials and the recruitment rates that have been adequate. These 
features have provided Portugal with a sound reputation conducting clinical trials.(39) 
On the other hand, in the year of 2011, INFARMED has only authorized the conduction of 87 new 
clinical trials in Portugal (figure 10), and according to the European clinical trial register, in 
portuguese territory, there are being conducted 650 clinical trials (ongoing). If we compare this 
number to countries similar to Portugal in terms of population numbers, such as Austria and 
Hungary, it is possible to conclude that Portugal has few clinical trials and that they need to be 
further promoted (table 2). A higher discrepancy is shown if compared to countries with bigger 
populations such as Spain, France or Germany (table 2). 
Table 2 - CT numbers in several European countries (Reproduced from ref. 40) 
Country Ongoing clinical trials 
Portugal 650 
Austria 1.050 
Hungary 1.684 
Spain 4.073 
France 2.640 
United Kingdom 4.807 
Germany 4.308 
 
Most of the clinical trials being conducted in the last 5-6 years in Portugal are phase III clinical 
trials, whereas phase I clinical trials are less performed (see table 3 and figure 10). In the trainee’s 
opinion this is due to the fact that phase I and II clinical trials require less CT volunteers so it is 
preferred to conduct this type of CT in high recruitment countries to achieve the recruitment 
commitment faster. In the case of phase III, since it is needed to confirm the information acquired 
in previous phases, the number of volunteers necessary is much higher and there is the need for 
more participating countries and therefore, this is where Portugal is frequently chosen to 
participate.  
Table 3 - Number of CTs being conducted in Portugal distributed by phases (Adapted from 
ref. 40) 
Clinical Trial Phase Clinical trial number 
I 4 
II 121 
III 497 
IV 82 
Total 650 
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Figure 10 - Number of clinical trial authorization requests to INFARMED distributed by 
phases (Reproduced from ref. 41) 
Earlier in January 2012, INFARMED publicly divulged that there were a total of 700.000 
participants in the clinical trials ongoing in Portugal. These clinical trials were mainly focused on 
the oncology area (about 40% of the trials), infectious diseases (about 11%) and neurology 
conditions (about 11%). Furthermore it mentioned that these clinical trials are being conducted in a 
total of 90 health institutions. The ones with more clinical trials are university clinical sites, mainly 
Hospitais Universidade de Coimbra, Santa Maria (Lisbon) e São João (Porto) and the oncology 
institutions located in Porto and Lisbon (IPO Porto e Lisboa).(42) 
The conduction of clinical trials in health institutions regards a number of advantages. The most 
relevant is the training in clinical research provided to the investigators that take part in the trial, 
which contributes to the promotion of the use of advanced and new medical practices in the 
institution. Other advantage has to do with the financial retribution that arises from the conduction 
of CTs in a specific hospital service. The financial agreement of clinical trials, most times, 
establishes a financial retribution to the investigators, hospital administration and hospital service 
where the trial is taking place. This monetary compensation can be used to improve the hospital 
service with new equipment and better infrastructures.(42) 
To the participants in CTs, there also are some advantages. In the trainee’s personal opinion, the 
most relevant is the patient’s access to new innovative therapies before they are available in the 
market. This is a major advantage in serious illnesses where the patient has few treatment options. 
In addition, when participating in a clinical trial the volunteer participant is highly controlled by the 
investigators, receiving medical care more frequently than if they were not part of a trial. Lastly, 
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there is the altruistic feeling experienced by these participants since they are contributing to the 
access to future important treatments. 
In spite of the advantages mentioned above, some experts say that the current Portuguese 
environment does not promote the development of many clinical trials, specially considering non-
European countries that have more competitive environments to conduct clinical trials. 
INFARMED has verified a decrease in the number of CTs authorization requests in the last 5 years, 
which confirms the statement above (figure 11). 
 
Figure 11 - Number of requests for clinical trial authorizations to INFARMED (Reproduced 
from ref. 41) 
 
Besides INFARMED, some experts also say that the future trend in clinical trials in Portugal is a 
decrease in the CTs performed. In 2009, a newspaper article, stating the opinion of João Barroca 
(vice-president of APIFARMA- Portuguese Pharmaceutical Industry Association), said that big 
pharma are taking CTs outside of Portugal, specially to Eastern Europe and the number of clinical 
trials in Portugal, even though it should have grown due to the requirement of more clinical trials 
for each drug, it has stagnated. This article alluded to the delay in the beginning of the recruitment 
period in several hospitals as the main reason to this trend, especially in hospitals where clinical 
research is not fully implemented. For instance, in Hospital Santa Maria, this approval process of 
may only take 15 days after which the recruitment period may start but other hospital may require 
months.(43) The Chief Executive Officer of the Champalimaud Breast Cancer Unit, Fátima 
Cardoso, also says big pharma industries are neglecting Portugal. She too, mentions the duration of 
the approval process as the main cause, but blames INFARMED and CEIC stating they should be 
faster to give authorization and should apply new legislation with faster approval times. Besides 
that, she highlights the need for a Portuguese network for sharing information regarding clinical 
 
 
29 
trials (44) which is being successfully implemented this year (PNEC, Portal Nacional Ensaios 
Clínicos – National Portal for Clinical Trials). 
Regarding the clinical trials approval time in Portugal, in 2006, it was made a comparative analysis 
using as an example an international multicenter phase III clinical trial. This analysis compared the 
Portuguese approval times with Denmark, Germany and Belgium. It was identified 4 critical time 
periods (figure 12) and compared between the 4 countries. The results are summarized in table 
4.(45) 
 
Figure 12 - The four critical periods from the submission of the CT to the last patient 
randomized (Reproduced from ref. 45, 46) 
 
Table 4 - The time between critical periods mentioned in figure 12 in 4 different countries 
(Reproduced from ref. 45, 46) 
Country Portugal Denmark Germany Belgium 
Period Time (in Days) 
1
st 
 74 22 86 88 
2
nd
 56,9 49,5 14 8,7 
3
rd
 1,53 26,75 9 17,3 
4
th 
 95,6 60,3 126 117 
Total (days) 228 162 235 231 
 
By analyzing table 4, Portugal is the country that takes more time between the competent 
authorities submission and the time it takes for the study site to be ready to perform the CT (130,9 
days). In this particular point the trainee agrees with the experts mentioned above, the time until 
approval is critical and if the sponsor is taking part in an European competitive recruitment study it 
will compromise the countries results. Portugal requires faster timelines to get INFARMED and 
CEIC approval. On the other hand, after the study site is ready to perform the trial, they seem to 
•The time 
between the 
submission 
of the  
authorization 
of the  
clinical trial 
and its 
authorization 
by the 
competent 
authorities 
1st Period 
•Time between the clinical 
trial authorization and the 
moment the study site is 
ready to perform the trial  
2nd Period 
•Time between the 
study site is ready 
to perform the trial 
and the moment 
the first patient 
enters the trial 
3rd Period 
•Time between the 
first patient 
entering the trial 
and the last patient 
being randomized 
4th Period 
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have the fastest first patient recruitment which is quite positive and suggests the clinical research 
teams are committed to the trials and that Portugal has an adequate recruitment rate.(46) 
To sum up and taking into consideration all the gathered information, Portugal seriously needs to 
create laws or other types of legislation that can guide the process of authorizing clinical trials in 
the health institutions in which they are going to be performed. On top of that there is the 
requirement to make the authorization process faster, which also applies to the INFARMED and 
CEIC. 
The decreased number of clinical trials in Portugal is concomitant to the period of the European 
R&D crisis. It is the trainee’s opinion that the current changes at an European level, may contribute 
to foster the performance of clinical trials in Portugal and change the expert’s opinion about the 
trend of clinical trials in Portugal. 
 
 
31 
2 - Regulatory Affairs & Clinical Research Procedures and Activities  
This chapter is going to focus on the activities developed by the trainee during the last ten months. 
These were mainly focused on clinical research, even though some Regulatory Affairs activities 
(Readability Tests) were performed. It is this chapter’s aim to provide a description of the 
procedures followed by the trainee to perform the requested activities and introduce the reader to 
the developed activities. This way, the current chapter is divided in 3 sections, each related to the 
main activities developed by the trainee: Readability Tests, Medical Writing Activities and Clinical 
Trials Monitoring. Each section has two main subsections: the first is the description of the 
procedure that is usually followed (therefore also followed by the trainee) and the second 
subsection alludes to which specific activity in the different areas the trainee was responsible for. 
 
2.1 - Readability Tests 
The trainee during the Biomedical Sciences Degree acquired some knowledge about the 
performance of readability tests. At Datamedica, she went through a training period about the 
readability tests consisting on reading the company SOP, protocols and reports of previous tests 
conducted at Datamedica. It was the company SOP that taught the procedures mentioned below to 
the trainee (subsection 2.1.1). Specific data about which readability tests activities the trainee 
performed is provided in subsection 2.1.2. The point of view of the trainee about the performance 
of readability tests at Datamedica is given in chapter 3. 
 
2.1.1 - Readability Tests Procedures  
The medicinal products that are marketed in the EU are required to be accompanied by package 
labeling and package information leaflet (PIL). The labeling is, in many cases, the only information 
that many people have access to about the use of medicines and they provide essential information 
about the safe and proper use of medicines. Therefore, it is extremely important that these elements 
are “easily legible, clearly comprehensible and indelible” as mentioned in article 53 of Directive 
2001/83/EC.(47) 
Furthermore, the same directive defined that the PIL “shall reflect the results of consultations with 
target patient groups to ensure that it is legible, clear and easy to use”, that is, it is necessary to 
perform user testing or readability tests to every medicinal product whose marketing authorization 
was granted after October 30 2005.(47) User testing is a way of testing the readability of a PIL in a 
target group. Basically, it is a way of identifying main problems with the PIL and to make sure the 
information provided is easily and correctly understood without mistakes. It allows the 
modification of the information, or the way the information is provided, in case there are any 
“problem areas”. In these tests it is used a full mock-up of the PIL that will be provided after 
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market approval.  
Datamedica’s Regulatory Affairs Unit is responsible for conducting Readability Tests in 
partnership with another company - Pharsolution. In this partnership, Pharsolution is responsible 
for adjudicating the test of a medicinal product to Datamedica and interacts with the client, and 
Datamedica performs the following tasks: 
 Revision of the package information leaflet; 
 Preparation of the readability test protocol; 
 Designing readability tests questionnaires; 
 Performing readability tests; 
 Compilation of the readability test data; 
 Preparation of the report of the readability test. 
Every time there is the need to perform a readability test Datamedica starts by selecting the team 
responsible to perform the activities related to the tests. 
 
2.1.1.1 - Revision of the PIL of a Medicinal Product 
The readability test procedure starts by receiving the PIL of the medicinal product that is applying 
for a marketing authorization from Pharsolution as well as the methodology of the Readability test 
to be applied. The PIL’s structure and content is revised to make sure there are no misspellings in 
it. If it is required to alter anything at the leaflet or if Datamedica suggests any change to the PIL 
Pharsolution is contacted and analyze the proposal with the client to see if he agrees or does not 
want to make the change. 
2.1.1.2 - Preparation of the Readability Test Protocol  
After the revision of the PIL, the protocol for the readability test of the medicinal product is 
prepared. The information regarding safety and efficacy information is identified (interactions, 
contraindications, safety precautions, side effects, etc) and selected for the development of the 
protocol and the readability test questionnaire. 
 In the protocol, the medicinal product and its regulatory history (that is, the reason why this 
medicinal product is taking a user testing) are introduced and the test methodology is drawn based 
on the indications provided. Pharsolution performs the final revision and the client signs and 
approves it. 
 
2.1.1.3 - Designing Readability Tests Questionnaires 
The readability test questionnaire to be used in the PIL user testing interviews is designed at the 
same time as the protocol and is a protocol attachment. 
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In the design of the questionnaires, it is crucial to assess the PIL of the medicinal product to find 
the most important information to be tested and then create questions addressing those issues. At 
Datamedica the applied questionnaire is divided in two parts. The first part is focused on key 
questions that reflect issues related to the safe and effective use of the medicinal product and assess 
the participant’s understandability and ability to find the information being asked. This part is 
usually constituted by 12-15 questions. The complexity of the PIL defines the number of questions. 
The topics of the questions should not be in the same order as the topics appear in the PIL. It is 
important to only address one issue per question and these should be open ended, clear and short. 
In addition the questions formulation should not be equal to what is stated in the PIL, but at the 
same time should not be too confusing.  
The second part of the questionnaire analyzes general characteristics of the PIL, such as the type, 
size and font, index, amount of information, titles, order of information, type of language, among 
others, and finishes by asking the participant to classify the PIL of the medicinal product. These 
characteristics are classified from 1 to 8 where 1 means very bad and 8 very good. 
Depending on the marketing authorization procedure
3
 the questionnaire may be developed in 
Portuguese or both English and Portuguese. Pharsolution must also revise the questionnaire. 
 
2.1.1.4 - Performing Readability Tests 
After the Protocol and the questionnaire have been approved these are printed out in corresponding 
numbers to the test volunteers needed and, the mock up of the PIL is sent out and printed exactly as 
it is going to be used after market approval.  
The test is composed by a series of face to face, structured sets of interviews where a range of 
different people need to be able to imagine being in need to use the medicinal product under 
testing.(47) 
The selected people should be representative of the population being treated. People who are 
directly involved with medicinal products (doctors, pharmacists, nurses, etc) are excluded from the 
test.  
Datamedica recruits the volunteers at Primary care units and pharmacies in the area of Lisbon 
through the establishment of a collaboration agreement between these institutions and Datamedica. 
Qualified interviewers randomly invite the patients visiting these primary care units or pharmacies 
to participate in the test and once accepted they are selected based on the inclusion and exclusion 
criteria defined for the test. The most important inclusion criteria include volunteers being able to 
                                                 
3
 If the marketing procedure is national the questionnaire is developed in Portuguese only. If it is 
decentralized, centralized or mutual recognition procedure the questionnaire will be both in English and 
Portuguese 
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read and write, aged 18 or more, and able to understand the test and give informed consent. 
Volunteers that have participated in previous readability tests, are using the medicinal product 
under testing or its active substance, are healthcare professionals and/or are employees of 
Datamedica or Pharsolution are excluded from the participation in the test. These can be more or 
less specific according to the type of drug being tested, especially if the medicinal product is only 
used in a certain type of population.  
These type of tests are diagnostic tests which means they do not need statistically significant data, 
only sufficient sample size to identify problems with the PIL.(48)  
Before taking the test, the interviewer orally explains the purpose and structure of the test and 
“reassures the participants that it is the document that is being tested not them”.(47) The 
volunteers must give its informed consent and are given 5 to 15 minutes to read and become 
familiarized with the PIL before taking the questionnaire. 
All volunteers are subjected to the same questionnaire whose questions are orally asked by the 
interviewer and he/she must answer using his/hers own words. If they are unable to find the correct 
answer, they must explain why they were not able to find the correct answer. When the requested 
information is found, the interviewer, through the “observation of how each participant handled 
the leaflet and searched for information, noting, for example, whether people become lost or 
confused”(47), classifies the degree of difficulty the volunteer went through in a four point scale 
(4-very easy; 3- easy; 2-some difficulty; 1-Very difficult; 0-Not found) and the time taken by the 
participant to give the answer.  
The number of volunteers that are subjected to the questionnaire will depend on the phases of 
development of the readability test. Usually there are around 20-27 volunteers divided in two 
phases: the Development phase and the Implementation phase (Main Test). 
The Development phase is composed by the pre-test (3 participants) and the pilot test (3-6 
participants)
4
. Both the pre-test and the pilot test have as main objective to test the appropriateness 
of the questions being tested at the questionnaire, that is, to make sure they will work in practice 
and to identify major problems with them and correct them before going to the implementation 
phase. If there is no need to alter the PIL, the test proceeds to the Implementation Phase. 
The implementation phase usually involves two rounds of 10 volunteers interviewed by the same 
interviewer. The objective of these main tests is to get information that the PIL of the medicinal 
product is clear, legible and easy to understand. The main test rounds will be repeated until the 
success criteria is met in two consecutive rounds: “A satisfactory test outcome for the method 
                                                 
4
 Usually it is Pharsolution that determines with the client the number of participants in the pre-test and the 
pilot test or even if there is going to be a pre-test - not all the readability tests have the pre-test. 
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outlined above is when the information requested within the package leaflet can be found by 90% 
of test participants, of whom 90% can show that they understand it. That means to have 16 out of 
20 participants able to find the information and answer each question correctly and act 
appropriately. However, it need not be the same 16 participants in each case. The success criteria 
will need to be achieved with each question. Results cannot be aggregated”.(47) If success is not 
met by the fifth round, the test is stopped and the PIL is deeply revised. It is important to notice that 
it is only possible to proceed to the next rounds if there is no need to revise the PIL. 
 
2.1.1.5 - Compilation of the Readability Test Data; 
The data acquired from the readability tests are compiled to a spreadsheet that summarizes the 
results of each participant from their demographic data to the understandability of each question by 
each participant, the duration taken for each question and the evaluation of the PIL made by the 
participant. The spreadsheet is also programmed to compile the data in graphs. 
 
2.1.1.6 - Preparation of the Report of the Readability Test 
After data compilation, it is time to make the test report. The final report summarizes the results 
and concludes whether or not the PIL has a good readability, based on the success criteria. It also 
indicates the mean overall classification of the PIL attributed by the participants (Very good PIL-
average between 7 and 8, Good PIL-between 5 and 6, Bad PIL, between 3 and 4 and very bad PIL 
average rating between 1 and 2). 
The final report analyzes the demographic data that can interfere with the results of the PIL such as 
the level of education, age group, use of written documents at work and other data about the 
volunteers.  
The report has a section for each test phase and a section of joint analysis of the data of main test 1 
and main test 2 (and other rounds if applicable). The data compiled in the spreadsheet is used in 
this report. 
After the report completion, the report is sent to Pharsolution with the spreadsheet and the data 
from the interviews performed for the test. Pharsolution revises and confirms the results and 
conclusions achieved, providing the client the entire package. 
 
2.1.2 - Readability Tests Activities Performed by the Trainee 
The trainee took part in several readability tests. In some there was a full participation and in others 
it was only partial. Table 4 identifies the therapeutic indication/area of the medicinal products that 
required Readability tests (until March 2012) where the trainee took part, with details regarding the 
therapeutic formulation and the type of marketing authorization submitted. Due to Confidentiality 
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issues the medicinal product name, its sponsor and other specific information about the medicinal 
product are not disclosed. The specific activities developed by the trainee about each medicinal 
product readability tests are indicated in the last column. 
Table 5 - Readability test activities developed by the trainee 
Therapeutic 
Area/Indication 
Therapeutic 
Formulation 
Regulatory History Readability Test Activities 
developed by the trainee 
 
 
Anesthetic agent 
(Generic) 
 
 
Solution for 
injection 
 
Marketing 
authorization 
application through 
national procedure 
 Revision of the PIL 
 Preparation of the readability 
test protocol 
 Preparation of the report of 
the readability test 
General 
anesthetic/ 
Sedative 
(Generic) 
 
Solution for 
injection 
Marketing 
authorization 
application through 
national procedure 
 Preparation of the report of 
the readability test 
 Compilation of the readability 
test data; 
 
 
Prophylactic 
therapy for 
migraines and 
headaches 
(Brand Drug) 
 
 
 
 
Capsules 
 
 
Marketing 
authorization 
application through 
national procedure 
 Revision of the PIL 
 Preparation of the readability 
test protocol 
 Designing readability test 
questionnaires 
 Performing readability test 
interviews 
 Compilation of the readability 
test data; 
 Preparation of the report of 
the readability test 
Prevention of 
bone 
complications and 
calcium reduction 
(Generic) 
 
Concentrate for 
solution for 
infusion 
Marketing 
authorization 
application through 
decentralized 
procedure 
 Preparation of the report of 
the readability test 
 
 
Analgesic and 
anxiolytic 
(Brand Drug) 
 
 
 
Inhalation gas 
 
 
Marketing 
authorization 
application through 
decentralized 
procedure 
 Revision of the PIL 
 Preparation of the readability 
test protocol 
 Designing readability test 
questionnaires 
 Preparation of the report of 
the readability Test 
 
2.2 - Medical Writing Activities 
Medical Writing is an integral part of clinical research and revolves around project documents and 
its activities include documents development, management, review and approval. It is a very 
important activity in clinical research since the success of a project highly depends on the array of 
documents that support it at any point of development.(49) 
 
2.2.1 - Medical Writing Procedures  
There are a number of activities related to medical writing from designing product development 
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plans, clinical trial protocols and amendments and other CT related documents (informed consents 
forms, manuscripts, monitoring plans, among others) to clinical study reports.(49) 
Datamedica performs some of those activities when requested by the client but in some cases it 
outsources medical writing activities, such as the development of some clinical trial protocols. 
During her internship at Datamedica the trainee had the chance to develop the following Medical 
Writing Activities: 
 Literature reviews for documentation and support of clinical trial projects; 
 Design of Case Report Forms; 
The procedures followed by the trainee to perform each medical writing activity are described 
below. 
 
2.2.1.1 - Literature Reviews to Support Clinical Trial Projects 
The following are the main situations at which Datamedica performs Literature Reviews: 
 To support a proposal for a new business opportunity 
 To develop a new clinical trial or epidemiological study  
 To support a medicinal product file 
 To support a clinical trial/epidemiological study document 
Most of the literature reviews performed by the trainee emerged after finding a new business 
opportunity, that required some theoretical knowledge, to support the service to be provided and to 
convince the client to allow Datamedica to be responsible for the service needed.  
 The first step in literature review is the realization of a team meeting to prepare the review. If the 
aim of the literature review is to support a new proposal for a client, this meeting is an opportunity 
to discuss and brainstorm around what is going to be proposed to the client. The remaining types of 
literature reviews mentioned only require some background knowledge about what is intended in 
the literature review, so this meeting works only as a way of providing information and delegating 
tasks. 
The result is usually the definition of the service that will be provided to the client, which is a draft 
of a design of a clinical trial (either interventional or observational) or an epidemiological study, 
the draft of a plan of action that resulted in the proposal to the client and the definition of a required 
literature review that would support some plan of action of the client. 
The next step is performing a search through published studies, articles, and/or undergoing or 
concluded clinical trials. These searches are usually conducted through Pubmed Database or other 
scientific database or clinical trial databases such as clinicaltrials.gov or clinicaltrialsregister.eu. 
Following this research, an assessment of the collected data is made and the most relevant data is 
compiled in a text document.  
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Trainee’s colleagues at Datamedica review the resultant document. They add their input and 
comments and the required changes are communicated to the author of the document. When no 
other change needs to be made the document is approved and provided to the client, to be used for 
the suitable purpose 
 
2.2.1.2 - Design of Case Report Forms 
Lastly, the trainee was also responsible for developing case report forms. Case Report Forms 
(CRFs) “are an official clinical data-recording document tool used in a clinical study” that 
“capture data that will be used to evaluate the research questions asked in the protocol and collect 
adverse event data for safety reports and processes”.(50) CRFs can also be a way of organizing 
data in surveys and epidemiological studies. 
CRFs are of great significance to the various players in the clinical trial process, since: 
 They help the study site members, specially the investigator to perform a specific 
evaluation; 
 CRA use CRFs to verify if the protocol is being followed correctly and to compare the 
study data with the source documents; 
 Datamanagers and Biostatistians use them to build database structures, develop and edit 
checks and to analyze and report the resulted data in the clinical trial report(51) 
The clinical trial protocol is very important in the creation of a CRF, since it determines what data 
should be collected on the CRF. So, the first step is to analyze the clinical trial protocol to 
determine which data is going to be collected in the trial and the data that should not appear on the 
CRF.  
CRFs, are important data collection tools about the trial and the selection of the information to be 
collected is critical. Then, this data is usually organized into sections such as: demographic data, 
vital signs, medical history/physical exam (baseline data), concomitant medication, etc. These are 
the most frequent modules/sections in CRFs about clinical trials, but each study defines the most 
appropriate.  
Then, there is the adaptation of a CRF template available at Datamedica to the clinical 
trial/survey/epidemiological study. The selected information is put in the CRF template taking into 
account that there should be minimal free text responses and most of the information requested 
should be in the form of questions with multiple choices. It is important to make sure the data is 
clearly outlined and the questions are concise and simple. To reduce misinterpretation, the 
developed CRFs are provided with instructions about its fulfillment.  
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To conclude, it is performed a revision of the resultant CRF by Datamedica’s staff involved in the 
conduct, monitoring, and analysis or reporting of the trial/survey/study. The CRF design steps are 
presented in Figure 13. 
 
Figure 13 - CRFs review process (Adapted from bibliographic ref. 51) 
 
The trainee witnessed that paper CRFs are being replaced by electronic CRFs, where data is added 
remotely though personal user access (login and passwords). Datamedica can also provide 
electronic CRFs if required by the sponsor, but it is necessary to subcontract companies specialized 
in the application/design of electronic CRF platforms.  
 
2.2.2 - Medical Writing Activities Performed by the Trainee  
The specific activities developed by the trainee are presented below. Due to confidentiality issues it 
was not possible to further develop this information. 
- Literature Review for documentation and support of clinical trial projects 
The information about the literature review projects that the trainee took part is presented in table 
6. 
Table 6 - Literature Reviews developed by the trainee  
Project Topic Objective Comments 
 
 
Hemorrhoid Disease 
 
 
General characterization of the 
disease and analysis of the impact 
of a specific medicinal product in its 
treatment 
This literature review was made to 
support the development of a new 
indication in hemorrhoids disease 
of a medicinal product from one of 
Datamedica’s clients. The created 
document would be part of the file 
to be submitted to the competent 
authorities (INFARMED). 
A specific property of 
coffee constituents 
Find the most suitable biomarkers 
for measuring a specific property of 
Literature review for a client 
proposal to support a possible 
CRF designer (The 
trainee was the CRF 
designer) 
• Review Protocol 
• Identify and Collect Data 
• Draft CRF 
CRF Reviewers 
(Datamedica 
Colleagues) 
• Review CRF 
• Comments and other input 
information back to designer 
CRF Designer  
• Updates CRF to include 
comments 
CRF Approval 
(Datamedica 
General Directors 
and the Clients) 
• Sign off 
• Printing the CRF Book 
(usually in triplicate to the  
different  stakeholders in a 
CT) 
• Distribution to the clinical 
trial sites 
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coffee constituents and the 
biological sample that provided the 
most accurate measure of the 
effect being analyzed 
epidemiological study 
C.Clostridium 
Infection 
General characterization of the 
infection 
Literature review for a client 
proposal to support a possible 
epidemiological study 
Varicose Veins 
treatment with a 
specific type of 
medicinal product 
formulation 
Find out if there are published 
studies about the treatment of 
varicose veins with the required 
formulation 
Analysis of a potential market for 
a medicinal product of one of 
Datamedica’s clients 
 
-Design of Case Report Forms 
There were developed two main types of CRFs by the trainee at Datamedica (see table 7). These 
were paper format CRFs and for both CRFs, the trainee also developed the correspondent 
instructions about CRF fulfillment. 
 
Table 7 - Types of CRF with the Trainee Participation  
CRF topic Objective 
 
 
Hepatitis 
 Developed for an epidemiology study with the main objective of 
characterizing the incidence and prevalence of Hepatitis in a specific 
population 
 CRF designed to help in the organization of the collected information and 
the resultant report  
 
Hemorrhoids 
 Developed to provide the client with a “possible” CRF to be used in a 
clinical trial of a new medicinal product for the treatment of hemorrhoids 
 
2.3 - Monitoring Activities – The CRA Role 
Every clinical trial requires monitoring. According to ICH Good Clinical Practice (see chapter 1 
section 1.3 - ICH) monitoring is defined as “The act of overseeing the progress of a clinical trial, 
and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, 
Standard Operating Procedures (SOP), Good Clinical Practice (GCP), and the applicable 
regulatory requirement(s)”.(52) Through clinical trial monitors (or CRA), who are responsible to 
perform the monitoring activity, a contact point between the trial sites and the sponsor is 
established.(52) In this section it is going to be discussed the monitoring activities performed both 
at Datamedica and Astellas. 
 
 
41 
 
2.3.1 - Monitoring Procedures  
The main purpose of monitoring is to make sure that: 
 The rights and well-being of the human subjects are protected; 
 The reported trial data are accurate, complete and verifiable from source documents; 
 The conduct of the trial is in compliance with the currently approved protocol/amendment(s), 
GCP and the applicable regulatory requirements.(52) 
Both Astellas and Datamedica perform monitoring of clinical trials. This activity is performed by 
CRAs
5
 (such as the trainee) or CRMs. There are a number of activities that comprise monitoring at 
Datamedica. These are: 
1. Document preparation and project revision 
2. Sites and investigator selection 
3. Clinical trial submission to regulatory authorities 
4. Monitoring visits 
5. End of trial submission to regulatory authorities 
The way these activities are performed usually is described in the SOP of the sponsor of the clinical 
trial. The sponsor provides Datamedica his SOP and the CRA or CRM goes through a training 
period focusing on them. Sometimes, it happens that, the sponsor does not provide his SOP and in 
those situations Datamedica’s Monitoring SOP are used to perform monitoring. Since the trainee 
was also at Astellas Farma Lda, she had a double SOP training period on clinical trial monitoring - 
the Datamedica training and the Astellas training. Below, there is a general overview of how 
monitoring was performed by the trainee. 
 
2.3.1.1 - Document Preparation and Project Revision 
As soon as the project is adjudicated the selected CRA/CRM performs a review of the project and 
analyzes all its documents - Protocol, Monitoring Plan, Informed consent, Case Report Form 
(CRF), Safety Reporting Plan, Investigator Brochure, etc in order to became familiarized with the 
trial, the current situation and to prepare the next tasks.  
In some situations this revision identifies missing elements to proceed with the trial activities. 
These missing elements may be important documents that may be asked to the sponsor or in some 
situations need to be developed in house (if the sponsor does not provide them), which occurred 
often at Datamedica. 
It may be also identified the need to translate to local language important clinical trial documents 
                                                 
5
 At some companies the CRA is called clinical trial monitor or just monitors, at Datamedica it is used the 
CRA designation. 
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such as the protocol synopsis and informed consent form and information sheet, among others. This 
is a quite frequent activity when talking about international clinical trials. Translations also work 
the other way around when there is the need to communicate or send clinical trial related 
documentation to a foreign sponsor. Usually the documents are translated to either English or 
Spanish. 
The next step usually performed is the preparation of the trial files - specially the Trial Master File 
(or Country File), in order to organize the clinical trial paperwork. In a more advanced state of the 
trial other files and folders need to be prepared (submission package, site file, investigator file, 
pharmacy file, etc). 
 
2.3.1.2 - Sites and Investigator Selection 
Clinical trials require the selection of the most appropriate health institutions and health 
professionals to conduct the trial. To do that, it is prepared a list of potential CT sites that is 
discussed with the sponsor. Sometimes, the places where to conduct the CT are already selected by 
the sponsor, so it is only necessary to contact the chosen sites and investigators in order to assess 
the availability and interest of the investigator/site to perform the trial. This first contact is usually 
made by telephone or email and as a result of the contact, it is scheduled a date to introduce the 
trial and provide the possible investigators with some study documents (confidentiality agreement 
& protocol synopsis). This can be considered the pre-study visit, which allows assessing the 
logistic capacity of the site to perform the trial (human resources, experience of the investigational 
team with clinical trials, the number of patients that may enter the trial, the facilities and equipment 
available at the site…) and discuss some CT requirements. This assessment is complemented by 
the feasibility questionnaire that is answered by the investigator during or after the visit; At this 
visit, discussion of some financial aspects of the trial and other specific procedures takes place, and 
some necessary documents are collected to the clinical trial submission (investigational team 
Curriculum Vitae, authorization of the chief of service where the trial is being performed, etc) if the 
site qualifies to perform the trial. Further contacts may be performed to clarify some issues with the 
investigational team and the site. 
 
2.3.1.3 - Clinical Trial Submission to Regulatory Authorities 
It is part of the monitoring activities the preparation and submission of the trial to the regulatory 
authorities (see chapter 1, section 1.3). According to the ICH-GCP guidelines and the Portuguese 
legislation, CEIC and INFARMED need to approve all clinical studies with IMP(s) prior to their 
initiation.(52, 53) Therefore, it is necessary to submit a request for authorization of a clinical trial 
to INFARMED and a request for opinion to CEIC. INFARMED and CEIC require the submission 
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of several documents that will allow to make an assessment/give an opinion about the trial. 
The CRA prepares the documentation to submit to these authorities. Frequent contacts with the 
clinical trial sites and the investigators are necessary to collect the documentation needed from the 
sites to be submitted. As soon as all the documentation is available it is submitted to these 
regulatory authorities taking into account the norms, guidelines and instructions available at their 
websites (see chapter 1, section 1.3). The files are submitted in a CD-ROM and paper format.  
This is not the only contact made with the competent authorities in the scope of monitoring. These 
regulatory authorities may ask for clarifications about the clinical trial while assessing it, which 
will require the CRA to provide new elements and clarifications. In addition, in case there are 
substantial alterations
6
 to the clinical trial and/or its document these shall be notified to these 
authorities.(54) Also, yearly, it is submitted Periodic Safety Update Reports (PSURS) to these 
authorities. 
Along with the submission to the regulatory authorities as mentioned above, it is necessary to get 
the approval of the board of administration and the local ethics committee of the clinical trial site. 
These two entities must be informed about the decision made by INFARMED and CEIC about the 
clinical trial application. 
Furthermore, it is required to register the clinical trial at the EudraCT database.(55, 56) This is a 
database of all the interventional clinical trials with medicinal products, which were submitted to 
the Regulatory Authorities and Ethics Committee, in the European Union. By registering the trial at 
the EudraCT database, an EudraCT number is attributed to the trial, identifying it. (55, 56) 
Lastly, the clinical trial data processing must be notified to CNPD (see chapter 1-section 1.3-
CNPD) and thus, registered at CNPD database. This notification is made through an electronic 
form developed by CNPD. 
 
2.3.1.4 - Monitoring Visits 
The sponsor usually defines the number of visits performed during the clinical trial. There are three 
types of monitoring visits to each trial site: pre-study visit (explained above), initiation visits, 
periodic monitoring visits and close out visits. With the exception of the pre-study visit, these visits 
will be explained below. 
 
                                                 
6
 Substantial amendments allude to those that have an impact on the: physical and psychological safety of the 
clinical trial participants; scientific value of the trial; conduction or management of the trial; Quality and 
safety of any medicinal product used in the trial. 
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2.3.1.4.1 - Initiation Visits 
After the authorizations to perform the clinical trial are granted (regulatory green light) and when 
the necessary conditions to perform the trial at the study site are verified, an initiation visit is 
performed by the monitors or CRA. This visit is performed to ensure that all investigators, co-
investigators, and other study staff members are fully informed about their responsibilities and 
obligations, concerning a clinical study and are fully prepared to conduct it according to the 
protocol and ICH-GCP guidelines. 
During this visit the pending documentation is collected, the CT protocol is introduced, as well as 
the Investigator Brochure, the CRF and other clinical trial materials including medication. One 
important characteristic of this visit is the provision of training about the GCP guidelines and other 
ICH guidelines. The notification of serious adverse events is explained as well as the informed 
consent procedure and other important characteristics of the trial. 
This visit is performed at each trial site but there may be a meeting organized by the sponsor to 
give training to (part of) the investigational teams - the Investigators Meeting. This meeting is 
important especially in international clinical trials. Basically, this visit prepares the sites for the trial 
and allows the investigational teams to clarify some doubts about the study procedures. Also, it 
provides the opportunity for the monitor to get to know the investigational team. 
After the initiation visit a monitoring report is made and delivered to the sponsor of the trial and a 
synopsis of the initiation visit is sent to the principal investigator of each study site as well as a list 
of pending issues that arose from the visit. 
 
2.3.1.4.2 - Periodic Monitoring Visits 
The number of periodic monitoring visits varies according to the type and characteristics of the 
trial. Usually the sponsor defines this number, but it may require some adjustment as the trial 
proceeds, especially if the recruitment rate at a specific trial site varies from what was expected, or 
if there have been a number of issues and protocol violations discovered in previous visits. The 
number of periodic visits should be specified in the monitoring plan, the protocol, the study 
contract or the study project. 
Each study site should be monitored as early as possible after the first subject has been entered and/ 
or initial data from the study have been received in order to check protocol understanding and 
compliance with GCP. These activities are important to assure the quality of the clinical trial data.  
The monitoring visit activities start before the visit itself, by performing the necessary activities for 
the visit (preparing documentation, scheduling the visit with the investigational team, assess the 
recruitment rate, among others).  
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During the monitoring visit the main activity is CRF review and source data verification, meaning 
checking if the data within the CRF of the trial is in accordance with the source medical documents 
of the patient. In addition, it is checked if the CRFs are being completed in due time and in full and, 
if they are accurate, consistent, legible and dated and signed by the investigator. This can only be 
done after checking if the patient has signed the informed consent form. Besides CRFs, it is 
important to assess if the trial study drug and materials are being used according to the trial 
protocol and, if there is the need for more trial materials (the accountability of the material is done). 
In addition, monitors verify if serious adverse events and other safety information have been 
correctly notified to Ethics Committee (EC), concerned Regulatory Authorities and to the Sponsor. 
Moreover, during these visits, the investigator file is updated, the study progress and recruitment 
rate is discussed, queries are resolved and protocol violations are identified and discussed.  
It is important that during the periodic monitoring visits the investigational team is available to 
discuss the issues mentioned above and to correct some errors or missing information on the CRF. 
After these visits a monitoring report is prepared and sent to the sponsor and another in-house 
revision of the CRFs is made.  
 
2.3.1.4.3 - Close - Out Visits 
This is the last monitoring visit that is made to a clinical trial site. After this visit the site is closed 
and the clinical trial is no longer performed at this site. This can mean that the trial has ended or 
that the clinical trial site was closed out due to reasons such as elevated number of protocol 
violations or low recruitment rate which did not justify the expenses on keeping the site open. 
The visit has to be carried out for all sites that have been initiated, even when no patients were 
recruited, and is performed in order to guarantee that all investigators, co-investigators, and other 
study staff members are fully informed about their responsibilities and obligations concerning the 
archiving of documents, according to the ICH-GCP guidelines. The visits are performed once the 
last patient has completed the study treatment and all follow-up procedures have been performed 
and all CRFs have been completed.  
This visit is prepared by revision of the periodic monitoring reports of the site and by preparing a 
list of documents to be archived at the investigator file. 
This visit usually encompasses the following activities: 
 File away documentation at the study sites files (pharmacy file, investigator File, etc); 
 Ensure that study data for each patient is complete and accurate; 
 Ensure that all adverse event reports are complete and accurate; 
 Collecting Signatures and original documentation related to drug accountability, patient 
screening/enrolment, responsibility log, etc; 
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 Supplying information about the time study data and material must be kept and informing 
that there is the possibility of occurrence of inspections or audits or queries resolution after 
the study site closes 
 Preparation of the shipment of clinical trial material to the sponsor 
Just like all other monitoring visits it is necessary to elaborate a close - out visit report and a letter 
of clinical trial site close out. 
 
2.3.1.5 - End of Trial Submission to Regulatory Authorities 
The sponsor is the entity responsible for determining when the clinical trial ends. Sometimes a 
premature termination may occur, which is decided either by the sponsor or the regulatory 
authorities. 
The clinical trial is considered finished when the clinical trial ended in all the national sites. After 
all the clinical trial sites are closed out, there are only few activities to be performed in order to 
consider the clinical trial as finished.  
The end of the trial must be notified to the regulatory authorities (INFARMED and CEIC), to the 
board of administration and the ethics committee of the clinical trial site. (54) 
In addition, it is necessary to return to the sponsor all the study material, which includes the used 
and unused medication, the files, and the CRF pages, among others. 
Apart from what has been explained, the CRA performs other essential activities to managing 
clinical trials such as the frequent progress reports to the sponsor, the registry and follow up of the 
patients that are part of the trial, in house revision of the clinical trial documents and safety 
information (Serious Adverse Events reports sent by the investigator), update of the Trial files, 
accountability of study materials, meetings with the sponsor, among others. These tasks are 
outlined in Figure 14, along with most of the above-described activities. 
Such other activities that the trainee performed during these last 10 months, a training period was 
required, that consisted on reading the company clinical research SOP, the ICH-GCP, the CEIC 
and INFARMED instructions related to clinical trials, the CNPD orientations and the applied 
legislation.  
 
Figure 14 - Clinical Trial Monitoring Activities 
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2.3.2 - Monitoring Activities Performed by the Trainee  
As mentioned in section 2.3.1, in the present section it will be described the Clinical Trials that the 
trainee took part both at Datamedica and Astellas Farma Lda described in the same order. Each 
trial will be briefly characterized and the main trial related activities performed by the trainee are 
going to be presented. 
It is important to mention that most of the CTs described below are interventional clinical trials and 
only one is an observational study.  
 
 Phase IV CT in the neurology therapeutic area 
This CT concerns a neurological condition (acute ischemic stroke) with a Spanish company as a 
sponsor, and performed in Spain, Germany and Portugal. It had as main objective the determination 
of the effect of a new compound in comparison with placebo, and was multicenter, prospective, 
double - blind, randomized and controlled study. In Portugal there were eight clinical trial sites. 
Each study subject in this study had five study visits during a period of 12 weeks and was 
administered two different formulations of either the study drug (IV and oral) or placebo.  
In this CT the trainee role focused on conducting monitoring visits to the sites. The trainee 
performed five monitoring visits on three different clinical trial sites. 
 
 Phase IV CT in the Renal Transplantation Therapeutic Area 
This CT was designed to comply with requirements of the United Kingdom Regulatory Authority 
(Medicines and Healthcare products Regulatory Agency (MHRA)) due to the fact the medicinal 
product under investigation is a generic drug product, that requires the performance of CT to 
demonstrate clinical safety and efficacy profiles similar to the brand product. In this particular case 
it was defined as efficacy endpoint the number of renal transplant efficacy failures in order to 
establish non-inferiority of this drug compared to the brand product. 
A pharmaceutical company in Brazil sponsored this clinical trial and it was performed both in 
Portugal and Spain. It had an uncommon design methodology, since it was designed to spare renal 
transplant patients to a CT, so there weren’t many changes to the common clinical practice 
introduced by the protocol. It was a multicenter, open label trial with historical controls
7
. The 
number of patients to be recruited to this CT was 250 for each group (500 total). The eligible 
patients were only subjected to three study visits (baseline visit, mid-study and final visit) during a 
six months period. It was supposed to be performed in six clinical trial sites but this number was 
                                                 
7
 It has two cohorts - prospective cohort and retrospective cohort (historical control group-patients that were 
treated with the brand drug product) 
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reduced to two sites since the medicinal product under study was already on the market for several 
years and there are already some better options to it. Therefore, few hospitals still use it.  
This trial was at the start-up phase when the trainee arrived at Datamedica and so, the activities 
performed were:  
 Clinical Trial Documents and Files Preparation and Revision  
 Selection of Clinical Trial Sites and Clinical Trial Investigators   
 Clinical Trial Submission to Regulatory Authorities 
 
 Phase IV CT in the Rheumatology Therapeutic Area 
Another Phase IV CT, in which the trainee took part, was a trial with the main objective to collect 
data regarding safety, efficacy and tolerability of a new dosage form of a medicinal product that 
combined two active substances. In order to accomplish that, the trial was a double blind 
randomized clinical trial with a four parallel treatment group. The four treatment groups were: the 
active substances individually in the doses already commercially available, versus the combined 
drug in the dose already marketed and the new dosage form. The efficacy assessment was based on 
a questionnaire that would evaluate the improvement of the condition under study. 
The recruitment aim of this clinical trial was 480 subjects (120 for each treatment arm) and they 
would only be part of the study for 14 to 21 days. They would only be exposed to the medicinal 
product during 7 days. The clinical trial patients would be recruited during a 12-month period. 
This was a national CT sponsored by an Italian pharmaceutical company that has a Portuguese 
affiliate (see chapter 1- subsection 2). This clinical trial will have six clinical trial sites.  
This trial is similar to the previously described due to the fact that when the trainee first arrived at 
Datamedica it hadn’t started as well and so the activities performed for this trial were similar to the 
ones mentioned above: 
 Clinical Trial Documents Preparation and Revision and Files Preparation  
 Selection of Clinical Trial Sites and Clinical Trial Investigators   
 Clinical Trial Submission to Regulatory Authorities 
 
 Phase II CT with a medical device to be applied to the Cardiology Therapeutic Area 
The trial about to be described has an interesting and different feature when compared to the 
previous ones since it focus on a medical device. The main difference from the procedures 
described on chapter 2 section 2.3, subsection 2.3.1.3, focus on the fact CEIC does not need to 
approve this type of trial. The other procedures are all the same and the trainee participated mostly 
on the clinical trial submission to regulatory authorities and documents preparation.  
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The CTs that will be described from this point on are the ones monitored at Astellas Farma. There 
were three trials that were monitored by the trainee and the European headquarters of Astellas 
(APEL) sponsored them all. These CTs focus on products developed by the company. 
 
 Phase III CT in the Urology Therapeutic Area 
The first Astellas trial being described alludes to the usage of a new product in the urology area, 
specifically in overactive bladder. The main objective of this trial was to assess the clinical efficacy 
of a new product in patients that were not satisfied with the therapeutic offer that was on the 
market. In order to achieve this primary objective the trial had the following design: international, 
double blind, multicenter, parallel group, with two treatment groups. One of the treatment groups 
was the new product and the other treatment group was a product of common therapeutic use in the 
treatment of overactive bladder. There were 36 countries participating in this trial in order to 
achieve a recruitment goal of 1992 subjects in just seven months of recruitment. In Portugal the 
trial had six sites with a recruitment commitment of six patients each. Each subject goes through 
five study visits in a period of 14 weeks. 
The trainee went through most of the trial life cycle, from submission, initiation and monitoring 
and so, a set of different activities were developed: 
 Clinical Trial documents preparation and revision (including clinical trial agreements, 
financial agreements preparation and clinical trial insurance requests) 
 Pre-study visits (feasibility visits) 
 Clinical Trial submission to regulatory authorities 
 Attending monitoring and investigators meeting 
 Clinical trial submission to the clinical trial sites 
 Performing initiation visits 
 Performing monitoring visits 
 
 Phase IV CT in the Urology treatment area 
Besides the CT above, the trainee also monitored another trial in the urology treatment area. This 
CT studies another product of Astellas but in patients with locally advanced prostate cancer. This 
trial compared two types of therapy with the same product in those patients. In terms of design this 
trial is also an international CT, multicenter, randomized, open-label and had as objective the 
inclusion of 700 subjects that have to go through two trial periods - the treatment period and the 
follow-up period. 
When the trainee arrived at Astellas Farma the trial was already going on since 2006 and had just 
finished the treatment period in the five clinical trial sites. This also meant that the sponsor wanted 
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to go through soft and hard database lock, which means, the need to solve all treatment period 
queries. This was the main activity conducted by the trainee while monitoring this trial. In addition, 
this study had a follow up period every six months after the treatment has finished, that required the 
need to contact the study subjects to see if they were still alive and so, the trainee had to keep track 
of these contacts informing the sites when it was time to contact the patient and if they did it 
indeed. 
 
 Observational study in the Pain treatment area 
The last study that was monitored by the trainee was not an interventional study. It was an 
observational study that analyzed the use in common clinical practice of an Astellas Product in the 
pain treatment area. This was a study conducted at an European level and multicenter. The main 
objectives were to assess the efficacy of their product in clinical practice and assess the time to 
retreatment with their product. The number of target subjects that would be treated with their 
product and assessed as part of the study was 1200 subjects.  
As an observational study the main activity that needs to be conducted by the sites, is the selection 
of the study subjects and collection of the information at specific timelines required by the trial. In 
Portugal there are 10 sites performing the study. 
This study experienced an interruption period that was imposed due to the need to clarify some 
issues with CEIC. The trainee was one of the Astellas’ team members that contributed to the 
“unblocking” actions required, as well as other activities that made the study evolve: 
 Pre-study visits (Feasibility visits) 
 Clinical trial Submission to the Clinical Trial Sites 
 Performing Initiation Visits 
 Performing Monitoring Visits 
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3 - Discussion  
This chapter presents the discussion of the aspects of the internship activities most positive or 
critical to the trainee, as well as, her opinion about them. In addition this chapter is also a reflection 
about the work experience acquired during the 10 months of the on the job training/internship. 
Ever since the first day of the internship the trainee became part of a new environment - the 
pharmaceutical world - working environment. It was one of the trainee’s goals to be introduced to 
the professional world as a CRA of the pharmaceutical world and Datamedica by choosing her to 
be part of the clinical investigation unit staff rapidly contribute to the achievement of the trainee’s 
goal (learning outcome 1 at this report introduction). It was at Datamedica that the trainee really 
got to know what were clinical trials, its importance to the pharmaceutical research world and most 
importantly, became aware of the different perspectives regarding clinical research - the 
perspective of the sponsor, the perspective of the investigator and the perspective of the contracted 
company that performed the trial. In a few words, the trainee fulfilled her learning outcome 2 of 
gathering know how about the CTs world. Moreover, Datamedica permitted and supported the 
trainee’s outsourcing to Astellas to gain more experience in a different pharmaceutical world 
environment but still as a CRA. Being a CRA is a huge challenge, everyday there is an activity that 
makes the trainee defy herself to perform it or solve it.  
 
As it was possible to see in the previous chapters of this report, even though the trainee was chosen 
to perform CRA activities at Datamedica, this CRO allowed her to experience other activities, 
which are directly linked to the achievement of learning outcome 10. 
Besides monitoring, one of the most frequent activities developed by the trainee, was the 
performance of readability tests procedures. As already discussed on section 2.1.2, the trainee was 
most frequently responsible for the development of the readability tests’ protocol and report. These 
two activities were not difficult, since they only required adaptation of a template-document 
already developed by Datamedica for each medicinal product. The report required more attention 
than the protocol design, because it needed an assessment of the graphics acquired after the user 
testing of the PIL, to reach a conclusion whether or not the PIL is readable. As the trainee gained 
practice creating the test protocol and report, she quickly realized which were the critical sections 
that required more focus and the activity became accessible to perform. 
The design of the questionnaire for the readability testing interviews and performance of the 
readability testing interviews was much more challenging. The difficult part was formulating the 
questions, because the answer could not be too straightforward to the volunteer, and at the same 
time could not confuse him. Also, in some PILs the important information was insufficient to 
create the 12 questions defined as a minimum and attention was necessary to neither formulate 
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irrelevant questions nor repeat information. On the opposite, there were PILs with too much 
information, which made the selection of these issues difficult, especially since it is important not 
to make the questionnaire too long, so that the volunteers don’t quit their participation in the 
readability test, influencing the results. In this activity the assistance provided by Datamedica 
colleagues usually responsible for these activities was essential as well as Pharsolution’s reviews 
and comments to the protocol and questionnaire.  
The performance of the readability tests interviews was by far the most difficult activity in the 
readability test procedures. The trainee only had the chance to perform it once, but considered it a 
hard task. First, not all the people addressed were keen on taking the test, in spite of the trainee’s 
assurance that they were not being assessed, but the document. This would slow down the 
recruitment and sometimes compromise the timeline of the entire process, especially in the 
medicinal products whose marketing authorization application required more volunteers for the 
readability test. Furthermore, the trainee had to deal with different volunteer’s personalities that 
were difficult to handle and that could interfere with the test results. This could be related to the 
place where the tests where performed, due to the fact the volunteers recruited were at a pharmacy 
waiting to get their medicinal products or wanting to get home after purchase the medicinal 
product. 
Finally, the trainee found the data compilation at the spreadsheet file as an interesting activity. The 
analysis indicated some “curious” facts, such as, the influence of the education degree on the 
evaluation of the readability, for example, people with higher educational degree would give lower 
scores to the different characteristics of the PIL being assessed. Moreover, these people would be 
the ones with faster answer times.  
The trainee had already heard about readability tests before during her Biomedical Sciences 
Degree. It was quite useful for the trainee to be part of this regulatory affairs activity at Datamedica 
since she applied the theoretical knowledge to the reality, which is part of the accomplishment of 
learning outcome 3 for this internship defined in the introduction. Datamedica’s structure and 
dynamics (section 1) provided the opportunity for the trainee to be part of this activity. In addition, 
the performance of readability tests was usually under a tight schedule, which required the trainee 
to, sometimes, put aside other activities and define priorities which contributed to improve the 
trainee’s organizational skills.  
The trainee also performed Medical Writing as part of the on the job training at Datamedica. 
Medical Writing shouldn’t be considered as a completely separated activity from clinical trials 
monitoring due to the CRA’s need to have a full inside knowledge about the clinical trial 
documents and be part of the process of development, organization and revision of these 
documents.  
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The literature reviews performed by the trainee to support CTs and other related activities, were 
one of the activities that required most effort to be accomplished. Firstly, since there were not many 
instructions about how the trainee should perform them and organize the resultant document, the 
trainee got worried, but soon realized that there was “free will” about the structure and content of 
the document, as long as the required content was organized and supported by reliable source 
documents. Also, in case of doubt her colleagues at Datamedica would always be available to 
provide assistance and support. These were some of the activities that better contributed to develop 
important team skills and good interpersonal relationships among the team colleagues and line 
managers (learning outcome 6 in the introduction). Secondly, some of the data/information 
required for the literature reviews was difficult to find even though the trainee was used to perform 
literature reviews and to search for information in articles and reliable websites. It was necessary to 
choose key terms that would lead to the desired information, that is, to find different strategies in 
the face of adversities as defined in learning outcome 9, in the introduction. 
On the other hand, when it was necessary to find information about a particular disease (incidence, 
prevalence, treatments used, etc) or the CTs/studies developed in those diseases, the trainee had no 
problems with this activity. 
Document revision and translation, two of the most common medical writing activities are part of 
the daily routine of a CRA (which constitutes more evidence about the connection between the 
medical writing department and clinical investigation). Right on the first month of the internship 
the first activity the trainee performed was the revision of the CRFs, informed consents information 
sheet and form and protocol. Being in contact with these documents for the first time and reviewing 
them was an interesting way of realizing which documents are essential in CTs, how they are 
usually structured and organized and what are the main points to pay attention to. This activity was 
how the trainee started acquiring in-depth knowledge about CT monitoring as mentioned in 
learning outcome 4 of the introduction. The easier documents to review in the trainee’s opinion are 
the informed consent’s information sheet and form. The most important characteristic of these 
documents is to see if they are clear and understandable to the patients and if they have all the 
information that CEIC requires to be provided to the patients. 
However the most interesting medical writing activity to the trainee was CRF designing. The 
trainee found it challenging to design CRFs without the guidance of a protocol. There were, 
however, different background tasks in those CRFs. In the CRF designed for hepatitis some of the 
data that should be collected was provided to the trainee, but on the CRF about acute hemorrhoidal 
crisis the trainee had to perform a search about the disease and select the information that should be 
part of the CRF. In general, the difficult part of designing the CRF was putting the data in the CRF 
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in a way that would be easily answered and without formulating questions that required an open 
answer. The utilization of a previously made CRF template was extremely helpful in this task. 
In general, the trainee feels that by being part of Medical Writing Activities, she had the chance to 
get to know another area of activity of the pharmaceutical world (which was also one of the goals 
of the trainee as becoming part of this world through the internship) that deals with documents, 
which the trainee feels that are indispensible in conducting clinical trials. 
 
Focusing on monitoring activities, these were and still are the most attractive activity to the trainee 
and the one that defied the trainee abilities and skills more often. With each clinical trial/clinical 
study the trainee had different challenges to solve. Throughout the next paragraphs are mentioned 
several situations of adversities faced by the trainee and the resolution of these problems which 
demonstrates the achievement of learning outcome 9 and also learning outcome 4 since the trainee 
had to acquire/develop specific skills to solve these situations. 
One transversal difficulty to all trials/studies is the struggle to contact the investigational teams of 
the trials/studies. The trial’s investigational team members, will frequently only be reached after 
days of several contact attempts by different means (email, telephone, contacting the hospital unit 
where they work, etc). The telephonic contact is the preferable mean of contact, especially if the 
mobile phone number is available to the CRA. To get through this difficulty, it is easier if at each 
clinical trial site, a team member who is usually more available is selected, in order to get things 
done easily.  
As most of the clinical trials monitored by the trainee were in the start-up phase, it was on this 
phase that most challenges and difficulties arose. The first difficulty found, related to the above 
concerns about investigational team availability, was the time it would take to collect the 
information and documents necessary to submit the clinical trial/study to the regulatory authorities. 
It is really difficult to define a very specific schedule for submission, since the CRA never knows 
when the principal investigator (which is the main contact at this phase) will be available to answer 
questions and give the necessary documents. One way to go around this situation is to schedule a 
day with the investigator and bring every necessary document prepared so that there are few 
pending issues (or none if possible, but unlikely). 
The preparation of financial agreements for the clinical trials was one activity the trainee had much 
difficulty with. The trainee was astonished by the background work required for this activity. It is 
necessary to be aware of the site requirements about clinical trial fees, as well as, already available 
templates the sites may have. It is also important to have input from the investigational team about 
the distribution of the fees amongst them and, to make sure that all involved parties are 
contemplated in the agreement (pharmacy, laboratory if needed, the administration board of the 
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site, etc) which means that it is necessary to discuss the contract with all these parties to reach a 
consensus. Some sites are easier to handle when it comes to contracts since they have few specific 
requirements and there is a contact person that deals with all contract related activities. At Astellas, 
adding to these already identified issues, there was the need to send the contracts for legal review 
by the international team which often led to subsequent changes of the trial contracts as well as 
developing bilingual contracts, that due to the technical contract language are difficult to do. This 
activity is an example of how learning outcome 7 was fulfilled since the trainee had to adapt to the 
Astellas’ rules and regulations regarding contracts. This task needs to be performed before 
submission to the regulatory authorities, since the contracts are evaluated by CEIC and 
INFARMED. However, since the administration board of the sites only evaluates the contracts by 
the time the submission dossier is submitted to them, there may be some changes made by the sites 
that need to be notified to CEIC and INFARMED.  
The Clinical Trials Submission to INFARMED, CEIC, and CNPD also brought a handful of 
challenges to the trainee. 
When submitting to all these authorities there are some requirements that need to be taken into 
account in order to have the submission process validated and evaluated. Some of these 
specificities are ambiguous and if not answered correctly, may lead to non-authorization of the 
trial. The most ambiguous situation experienced by the trainee occurred with CNPD request for 
information after submitting their form. The CNPD requested information about transmitting 
information to countries outside EU, which lead to a request to the sponsor - APEL to prepare and 
sign a variety of new contracts with their vendors. Consequently delays occurred compromising the 
study timelines. In a CT performed in 36 countries only CNPD requested information about this 
issue which makes the trainee think that CNPD is a very competent entity, but also very strict. This 
is one of those issues that, as mentioned in section 1.5, may compromise the future development of 
CTs in Portugal. 
In addition to CNPD, CEIC is also a very strict Committee, especially when assessing the material 
directly delivered to the study participants (e.g. informed consent). The main problem with CEIC is 
the time they take to evaluate the trial which may be extended if they request for clarifications. The 
trainee thinks that the clarification period is important but, she went through a situation where the 
clarifications asked were the correction of spelling errors and deleting commas, which even though 
it is important, it seems exaggerated due to the extension of the period to get their response.  
 In terms of submission to the clinical trial sites, it is important to be sure that all their requirements 
are fulfilled. In those sites that have a high number of requirements, it is more difficult to gather all 
the documentation. One setback with regard to the submission to the administration board is the 
fact that few clinical trial sites accept the submission dossier before CEIC’s, INFARMED and 
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CNPD authorization, which contributes to delaying the time to get the trial to start. This was 
critical for the trainee, because of a really aggressive and competitive timeline of an Astellas’ 
Urology CT with a seven months recruitment period. Considering CEIC’s opinion was only 
available by the time recruitment was already on its third month, the crucial impact of these 
authorities approval times becomes evident.  
Regarding the observational study monitored by the trainee, this study did not require approval 
from INFARMED and CEIC, only from the Local Ethics Committee and Administration Board. In 
some situations this means quicker approvals and easier beginnings (the trainee experienced a site 
that approved in one month and a half) but it may also mean long delays (on the other hand the 
trainee experienced a site that took nine months to approve a study).  
During submissions and approval periods it is important to keep the investigational site staff teams 
interested in the trial. The importance of this update was evidenced with the Datamedica CT on the 
rheumatology area, whose regulatory authorities submission were delayed and some of the already 
selected sites quit the trial due to loss of interest in the trial. 
At Astellas, while submitting the trial to the authorities, the trainee had the opportunity to attend an 
Investigator Meeting organized by APEL. This meeting was attended by two members of the 
investigational team of each site at the international level. This was a valuable experience for the 
trainee contributing to create stronger bonds with the investigational teams, by accompanying them 
during this meeting and making sure they had everything they needed while they are attending the 
meeting. These meetings contribute to establish a big contact network with professionals all over 
the world (learning outcome 5). These meetings were considered extremely important in the CTs 
context, as they allow to pass on and explain the trial to everyone involved, at the same time, and in 
the same manner. Furthermore, the participation of the international team members allows the 
exchange of ideas and the clarification of issues about the trial with everyone. During the same 
period of the investigator meeting, there was organized a monitoring meeting that lasted longer 
than the investigator meeting, and its main goal was to explain the CT procedures in detail to the 
CRAs.  
The trainee considers monitoring visits to CT sites as the most important monitoring activities. The 
trainee performed three types of monitoring visits: pre-selection visits, initiation visit and periodic 
monitoring visits.  
The pre-selection visits require some deep knowledge about the CT to answer all the questions that 
may rise, while introducing it to the investigational site and the principal investigator. While 
conducting this visit, it is important to contact the right person. Usually, the first contact is with the 
head of the hospital unit where the study shall be conducted and he then points the principal 
investigator of the trial. Sometimes, the first contact may be directly with the principal investigator. 
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This situation occurs when the principal investigator is already known, that is, it has already 
performed one of the company trials. In the pre-selection visits there are three different possible 
results: either the site accepts the trial and Datamedica or Astellas select it, or the site rejects the 
trial, or the site wants to conduct the trial but Astellas or Datamedica think the site does not have 
the suitable conditions and does not select it. While performing selection visits at Datamedica the 
trainee came across several rejections from the clinical sites due to inability to recruit patients with 
the required profile and at Astellas, there were situations where the sponsor did not consider the 
site had the suitable conditions. A major reason not to choose contacted sites is the understanding 
that the site staff does not have enough time to perform the study, and some of its members may 
not be interested in the trial, or there may be some issues with the administration board that makes 
it difficult to obtain CT approval.  
Initiation visits were frequently performed by the trainee at Astellas and the main lesson taken from 
these visits is that the CRA must really understand the trial/study and be able to answer any 
question that may rise, because there are investigational site staff teams that are more difficult than 
others and ask about every detail of the trial. Usually the main issue with the initiation visits is that 
they take between two to four hours, depending on the trial, and the investigational team must be 
able to be present during this visit. It had happened more than once that the trainee had speeded up 
the initiation visit presentation because the team was getting restless and wanted to go back to 
work. Also, when the investigational team is big, it is difficult to schedule an initiation visit that 
can be attended by all team members. These visits usually are the first contact of the CRA with the 
entire team and it is how they learn how to conduct the trial correctly. 
Periodic monitoring visits have different challenges. In these visits the trainee was in contact with 
the investigators and talked about how the trial was being conducted by the investigational team at 
the trial sites. This is very important since it shows that there is a commitment from both parts in 
performing the trial correctly and allows discussion of some problems that may have risen and the 
solutions to them. Again, these contacts should not occur only through periodic monitoring visits 
but frequently, by both telephonic contact and email. The CRA should always be available to meet 
the site staff team if requested. The most difficult activity in these visits is the source data 
verification that allows detecting any issue that may come up and ensuring the data are accurate, 
and the trials are being conducted properly and according to GCP. To do this, it is necessary to 
adapt to the different source documents of the different CT sites. When performing periodic 
monitoring visits, a comparative analysis is made between the information at the source documents 
of the patient and the information added to the CRF. To do this correctly and accurately it is 
important to know how the files of the subjects are organized to find the information that needs to 
be confirmed. The problem is that each CT site has its own organization and the CRA needs to 
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adapt to each unit organization. In addition, if a subject has had adverse events, it is necessary to 
verify if the AE has been reported correctly which is usually a laborious and time-consuming task. 
Usually the investigational team hasn’t reported the AE and it is necessary to report what was 
found right away. Furthermore it may be detected incomplete or wrongly added data at the CRF 
and, since the investigational team is the only party authorized to make data changes, both at the 
CRF and source documents, the CRA usually calls the investigator during the visit to correct the 
information. This means that the monitoring visits will take longer, according to the investigational 
team availability. This reflects the importance of scheduling the periodic monitoring visit with the 
investigational team. One important feature that is worth mentioning is the fact that periodic 
monitoring visits can flow easier at the CT sites that have study site coordinators which can solve 
some problems detected by the monitor and correct CRFs, without having to wait for the 
investigators. In those cases, most of the issues that arise are dealt with the study site coordinator, 
which is, as the name indicates, in charge of coordinating the trials. 
Despite what has already been discussed, the trainee would like to mention the importance of 
frequently updating the sponsor about the trial that is being performed. For example, at Astellas 
with the international trials, every month or even every week, a teleconference was scheduled with 
the sponsor and the other affiliates that were performing the trial in their countries. These 
teleconferences were one of the most important activities that the trainee had to perform and, 
usually, the study manager of the trial conducted them.  
In general, while at both Datamedica and Astellas Farma the trainee had the chance to realize the 
importance of monitoring and of clinical trials in general, especially for the subjects taking part in 
clinical trials for whom it is needed to protect their rights and well-being which is part of the 
CRA’s responsibilities since these subjects are helping in getting new innovative products to the 
market and to improve general healthcare. Knowing that she is being part of something this 
important made the trainee feel great. 
It should be mentioned that, not only through the activities developed, Datamedica allowed the 
trainee to establish a professional contact network (learning outcome 5). Datamedica provided to 
the trainee the opportunity to attend the European Meeting organized by DIA (Drug Information 
Association). DIA - 24th Euromeeting was considered one of the most positive and rewarding 
experiences to the trainee. This meeting was attended by thousands of professionals related to the 
pharmaceutical business, from different areas/departments and promoted networking between the 
attendees with speed networking, or networking lunches, etc, to exchange experiences and advices 
between them about careers, future etc. In addition this meeting also had booths/stands from 
different companies around the world, some of which the trainee had never heard of and that gave 
her a perspective of what was out there for career development. It was the first time she had 
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attended an event of this dimension and the experience was so valuable that the trainee intends to 
attend more of this meetings. 
In the above paragraphs it were discussed the activities the trainee had the opportunity to perform 
during these ten months. In the following paragraphs a brief description about the activities that the 
trainee did not have the opportunity to do is being discussed. 
The most important activity the trainee identifies as not being able to perform and that interferes 
with the learning outcome 2 about the clinical trial monitoring know how and responsibilities is the 
performance of CT close out visits. These are the only type of monitoring visits the trainee has 
never performed or even witnessed. This situation occurred because most of the trials the trainee 
was involved were at their set up phase or recruitment. Only the phase IV neurology CT was about 
to close but those visits were only performed after the trainee went to Astellas Farma Lda. 
The trainee also would have liked to use the information systems created at Datamedica, especially 
COATI, since according to the description of the program and the opinion of the Datamedica’s 
colleagues it is a very useful tool for clinical trial monitoring. The problem with this system is the 
fact that does not run in the trainee laptop. One other activity the trainee would have liked to do 
was, the possibility of performing pharmacovigilance activities at Datamedica. This because, since 
she was able to perform Regulatory Affairs Unit activities, which is linked to the 
Pharmacovigilance Unit, if she had been given the opportunity to perform some of these activities, 
she would have fulfilled learning outcome 10 (performing activities not related to CT monitoring) 
in a wider extent and would have given the trainee a wider knowledge about other pharmaceutical 
industry areas.  
To complete this chapter, the trainee would just like to discuss how being part of Astellas and how 
the size of this company changed the way her work was performed. First, since the trainee was 
working in one of the CT sponsor’s affiliate it would contact the sponsor more easily. Secondly, 
Astellas has many medical sales representatives that promote Astellas’ products through the 
doctors and hospitals. These are the same institutions/investigators chosen for the clinical trials. 
This way, when the trainee was unable to reach a site team she could contact the sales 
representatives to help her. Finally the fact the medical and regulatory affairs department was 
bigger than the clinical investigation unit at Datamedica and the fact that at Astellas there was a 
Clinical Trial Assistant to help the trainee with files and folders, the work was better organized.  
Finally, the trainee just wanted to acknowledge the change witnessed with the creation of 
Datamedica Angola. When the trainee was outsourced to Astellas, Datamedica had just created 
Datamedica Angola. The creation of this new affiliate was the way Datamedica found to deal with 
the economical crisis in Portugal. Angola is a receptive country in terms of pharmaceutical research 
and it is much more profitable to perform clinical trials in Angola, since healthcare is cheaper and 
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there are much more CT volunteers. For now, in Angola, Datamedica is performing training in the 
correct ethical principles and good clinical practices to develop the company further. It is very 
positive for both Datamedica and Angola to have this new company. From Angola’s point of view 
it is good that Portugal is investing there to raise the economy and to Datamedica this is the first 
step taken to conquer the international market.  
Lastly, with every activity the trainee had to perform she performed the best way she knew in a 
careful way and most of all successfully which fulfills the learning outcome 8. 
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4 - Conclusion 
The ten months that have gone by were a unique experience to the trainee. They have marked the 
trainee’s entrance in the professional world, which, as already discussed, was considered very 
positive. Datamedica welcomed the trainee and took care of her until she was ready to proceed by 
herself in a new company (Astellas) with a different dynamic and always backing her up - the 
trainee considered that being outsourced to Astellas was the best way to learn and grow in this 
business by herself. This was how the trainee was introduced to the professional world to develop 
her career and how she was brought closer to the pharmaceutical research world, specifically the 
clinical trials world. 
By being part of two companies performing CTs and all its related activities the trainee got to know 
how this business worked from two perspectives (the company that sponsors the trials and the 
company to where services are outsourced) and what her responsibilities were and became a 
professional CRA. In addition as part of both Datamedica and Astellas all the theoretical 
knowledge gathered in the previous years of education finally gained practical application and the 
trainee realized the importance of this knowledge even though there were required some 
adaptations to reality.  
The experience of these several months provided the trainee with skills and expertise essential to 
CT monitoring that could never be acquired through books or lectures, such as, how should the 
investigators be preferably contacted? In what manner can CRA offer assistance to investigators? 
How to strengthen relationships between CRAs and monitors? Working as a CRA during these last 
months has changed the trainee’s personality – she became more self-confident to talk to the 
investigational teams of the clinical trial and argumentative, which makes a difference in the 
CRA’s world. Also, these two companies allowed the trainee to create the first contacts of a 
professional network in the pharmaceutical research business, which is of great importance, 
especially in the Portuguese economical situation. 
In the trainee’s opinion there isn’t a better professional activity to collaborate with a variety of 
professionals and to develop team skills and good interpersonal relationships. The trainee got to 
know and work with physicians, nurses, pharmacists, study managers, medical managers, medical 
advisors, medical information delegates, etc and realize their impact and role in clinical research.  
With every activity the trainee faced during these 10 months she performed it the best way she 
knew. Sometimes she faced difficulties, e.g. with financial contracts and authorities’ authorizations 
but with her commitment and support from colleagues, she was able to accomplish the proposed 
activities and solve adversities. The trainee considered being able to face adversities a major 
achievement. 
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 Furthermore, she was able to perform activities outside CT monitoring that was the chosen area of 
the internship, such as medical writing activities and readability tests as already mentioned in the 
previous sections which evidences the completion of the last defined learning outcome. 
By analyzing the defined learning outcomes, in a few words, the trainee considers that in general 
terms they were all achieved leading to the conclusion that Datamedica is a good place to take the 
on the job training / curricular internship. By having experienced the two stakeholders’ 
environments (Astellas and Datamedica) and identified the benefits of being part of a big 
pharmaceutical company, the trainee considers that Datamedica was the suitable place to start out 
the CRA career, due to the fact big pharma companies such as Astellas do not focus exclusively on 
clinical trials and clinical research and do not have large teams of CRA/CRM. At Datamedica due 
to high focus on clinical research the trainee had more colleagues performing clinical trials 
monitoring to learn from, which was essential to the trainee, especially when she was outsourced to 
Astellas. Besides experience, first perspective on the clinical research-working environment, 
company dynamics and staff responsibility, Datamedica provides opportunities to expand the 
trainee curriculum in addition to good companionship, teamwork values and to personal growth. 
 
 
 
 
 
65 
References  
1. Datamedica. Datamedica-A empresa (Web page) Lisboa: Datamedica 2008 [updated 2007; cited 
2011 November 19]; Available from: www.datamedica.pt. 
2. Portugal AFL. Astellas Leading Light for Life. (Web page).  Lisboa: Astellas Farma Lda Portugal 
2009 [cited 2012 April 2]; Available from: http://www.astellas.com.pt/pt/astellas-portugal/. 
3. Roche. Roche Research & Development Overview. (Web page). F. Hoffmann-La Roche. 2012 
[updated 2012; cited 2012 April ]; Available from: 
http://www.roche.com/research_and_development/r_d_overview.htm. 
4. GlaxoSmithKline. GSK Science & innovation.  (Web page). England and Wales 2012 [updated 12 
March 2012; cited 2012 April ]; Available from: http://www.gsk.com/research/science-and-
innovation/index.htm. 
5. AstraZeneca. AstraZeneca Research.  (Web page).  AstraZeneca International. 2012 [cited 2012 
April]; Available from: http://www.astrazeneca.com/Research. 
6. Smaglik P. Nature Jobs. Nature. 2007 11 January 2007. 
7. Akst J. Contract Research on the Rise. (Web Page). The Scientist- Exploring Life, Inspiring 
Innovation. 2009 [cited 2011]; Available from: http://classic.the-
scientist.com/?articles.view/articleNo/27578.  
8. Jewett G, Hassan A. Talking R&D: Strategic vs full service CRO. (Web Page) Inpharm.  2010 [cited 
2012 February 11]; Available from: http://www.inpharm.com/news/talking-rd-strategic-vs-full-service-cro.. 
9. MedSource. Clinical Research Organization, Cancer Oncology CRO Clinical Trials. (Web Page) 
MedSource-CRO. 2010 [updated 2010; cited 2012 February 11]; Available from: 
http://www.medsource.com/. 
10. Surrey U. Surrey Clinical Research Centre-University of Surrey.(Web page).  Guidford. University 
of Surrey [cited 2012  February 11]; Available from: http://www.surrey.ac.uk/crc/. 
11. Roland CL, Litka P. Clinical Trial Operations. In: Evens RP, editor. Drug and Biological 
Development:From Molecule to Product and Beyond: Springer; 2007. 
12. Ledford H. Contract Investigators Nature 2010 8 July 2010:2. 
13. Denver OoRCUoC. Clinical Research Support Center. (Web Page). Colorado, Denver University of 
Colorado 2012 [cited 2012  April 14]; Available from: 
http://www.ucdenver.edu/academics/research/AboutUs/regcomp/ClinicalResearchSupportCenter/Pages/defau
lt.aspx. 
14. Center TUoK-C, Authority KB, Innovation CfAM, Entrepreneurship K-TFo. The new Role of 
Academia in Drug Development- New Competencies, New Results Driving New Paradigms in Cancer 
Research. Kansas: Kauffman Foundation2010. 
15. Comission E The new SME definition-User Guide and model declaration, Publication EaI. 
16. Carr M. SME's in Clinical Trials. (Website)  London; [updated 2010; cited 2012 February 11] 
Available from: http://ec.europa.eu/research/health/pdf/event05/melanie-carr_en.pdf. 
66 
17. Comission E Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001, 
Union EPatCotE (2001). 
18. Comission E. Application of the EU law-Directives Definitions. (Web Page). European Comission. 
[updated 2012; cited 2012 June]; Available from: http://ec.europa.eu/eu_law/directives/directives_en.htm. 
19. Comission E. Medicinal Products for human Use- Clinical Trials General Information.  (Web Page). 
European Comission. 2012 [cited 2012 April 2]; Available from: http://ec.europa.eu/health/human-
use/clinical-trials/index_en.htm. 
20. Comission E. EudraLex - Volume 10 Clinical trials guidelines. (Web Page). European Comission. 
2012 [updated 11th July 2012; cited 2012  April 2]; Available from: 
http://ec.europa.eu/health/documents/eudralex/vol-10/index_en.htm. 
21. INFARMED. Medicamentos de Uso Humano-Ensaios Clínicos. (Web Page) INFARMED; 2011 
[updated 2011 September 12; cited 2011  December 4; Available from: 
http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/ENSAIOS_C
LINICOS. 
22. Agency EM. EMA What we do. (Web Page). London. EMA. 2012 [cited 2012 April 2 ]; Available 
from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000091.jsp&m
id=WC0b01ac0580028a42. 
23. ICH. ICH History (Web Page). ICH.  2011 [cited 2011 December 22 ]; Available from: 
http://www.ich.org/about/history.html. 
24. INFARMED. Sobre o INFARMED. (Web Page). INFARMED. Lisboa [cited 2012  January 24]; 
Available from: http://www.infarmed.pt/portal/page/portal/SOBRE_O_INFARMED/APRESENTACAO. 
25. CEIC. CEIC: Missão. (Web page). CEIC.  Lisboa [cited 2012  January 22 ]; Available from: 
http://www.ceic.pt/portal/page/portal/CEIC/QUEM_SOMOS/MISSAO. 
26. CNPD. A CNPD. (Web Page). CNPD.  Lisboa 2012 [cited 2012  January 24]; Available from: 
http://www.cnpd.pt/bin/cnpd/acnpd.htm. 
27. Silverman RB. The Organic Chemistry of Drug Design and Drug Action. 2nd Edition ed. Hayhurst 
J, editor: Elsevier Academic Press; 2004.. 
28. ICH Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing 
authorization for pharmaceuticals, M3(R2) ICH (2009). 
29. CPMP/ICH ICH Topic E8-General Considerations for Clinical Trials, CPMP/ICH/291/95 Agency 
EM (1998). 
30. Communities CotE Analysis of the effects of a Joint Technology Initiative (JTI) in the area of 
INNOVATIVE MEDICINES -Impact Assessment, SEC(2007) 568 EC (2007). 
31. IMI. The Innovative Medicines Initiative - Assessment  of Economical and Societal Effects IMI 
2007. 
32. IMI. The Innovative Medicines Initiative (IMI)  Scientific Research Agenda  Revision 2011 2011. 
33. IMI Fact Sheet-IMI Scientific Research Agenda-Revision 2011, IMI (2011). 
34. Scott A Waldman AT. Patient-centric clinical pharmacology advances the path to personalized 
medicine Future Medicine Ltd. 2011:4. 
 
 
67 
35. Hamburg MA, Collins FS. The Path to Personalized Medicine. The New England Journal of 
Medicine. [Perspective]. 2010 July 22, 2010;363(4):4. 
36. Leon Jd. Pharmacogenomics:The Promise of Personalized Medicine for CNS disorders. Nature. 
2009:14. 
37. PharmaPortugal. Portugal In Brief. (Web page) APIFARMA.INFARMED. 2011  [cited 2012 
February 7]; Available from: http://www.pharmaportugal.com/facts_figures2.htm. 
38. Financetar. Medical&Pharmaceutical Products- Industrial Sector Overview. (Web page) Financetar 
SA. 2003  [updated 2003; cited 2012 February 7]; Available from: 
http://www.portugaloffer.com/pharma.html. 
39. Gallagher R, Garcia MA. The Clinical Trials Directive in Portugal. (Web page) ADVANSTAR 
2005 [updated 2012; cited 2012 February 7]; Available from: 
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Regulatory/The-Clinical-Trials-Directive-in-
Portugal/ArticleStandard/Article/detail/168944. 
40. EU Clinical Trials Register- Search For Clinical Trials [database on the Internet] 1995-2011 [cited 
2012 February 8 ]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=&country=pt&status=ongoing. 
41. INFARMED. Estatisticas de Avaliação de Ensaios Clínicos pelo Infarmed. (Web page) 
INFARMED.  Lisboa 2006-2011 [updated 2012 January 13; cited 2012 February 22]; Available from: 
http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/ENSAIOS_C
LINICOS/ESTATISTICAS/Tab. 
42. Lusa. Ensaios Clínicos envolvem sete mil pessoas em Portugal. (Electronic Article) RTP notícias. 
[cited: 2012 Jan 30]. Available from: 
www.rtp.pt/noticias/index.php?article=522495&tm=8&layout=121&visual=49. 
43. Ribeiro AT. Farmacêuticas desistem de ensaios clínicos em Portugal. (Electronic Article) Diário de 
Notícias Portugal.[cited: 2012  Novembro 6]. Available from: 
http://www.dn.pt/inicio/portugal/interior.aspx?content_id=1412180 
44. Lusa/SOL. Farmacêuticas excluem Portugal dos países para ensaios clínicos. (Electronic Article)  
SOL. [cited: 2011  Abril 12]. Available from: 
http://sol.sapo.pt/inicio/Sociedade/Interior.aspx?content_id=16584. 
45. Boaventura I, Silva HGd. Análise Comparativa dos tempos de Aprovação de um ensaio clínico de 
fase III em Portugal: a propósito do inibidor da integrase MK-0518.  VIII Congresso Nacional de 
Infecciologia Outubro 2006. 
46. Boaventura I. Round Table- Clinical Trials in Portugal. In: Forte M, editor. Pharmaceutical 
Biomedicine Master's Degree- Clinical Development; INFARMED2010. 
47. General EC-EaID Guideline on the Readability of the labelling and package leaflet of medicinal 
products for human use, ENTR/F/2/SF/jr (2009)D/869 Commission E (2009). 
48. MHRA Questions and Answers to Support the MHRA Guidance on User testing, MHRA (2005). 
49. QUINTILES. Medical Writing Services. (Web Page). QUINTILES.  [cited 2012 March 11]; 
Available from: http://www.quintiles.com/clinical-services/medical-writing/medical-writing-services/. 
68 
50. Center ICSS. CRF Development. (Web Page) ICSC;  [cited 2012 March 9]; Available from: 
http://www.icssc.org/services/services-crfdevelopment.html. 
51. Mailhot DW. Design of Case Report Forms In: Designers C, editor.2006. 
52. CPMP/ICH ICH Topic E6 (R1)-Guideline for Good Clinical Practice, CPMP/OCH/135/95 Agency 
EM (2002). 
53. República Ad Lei n.º 46/2004, de 19 de Agosto Aprova o regime jurídico aplicável à realização de 
ensaios clínicos com medicamentos de uso humano , República Ad (2004). 
54. INFARMED. Formato da documentação a ser apresentada ao INFARMED, I.P.  no âmbito de um 
pedido de Autorização de Ensaio Clínico  e de Alteração Substancial e de uma notificação de Conclusão de 
Ensaio Clínico INFARMED2012 2012-06-01. 
55. INFARMED. Base de Dados Europeia (EudraCT). (Web Page) INFARMED.  2012 [cited 2012 
February 27]; Available from: 
http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/ENSAIOS_C
LINICOS/EUDRACT. 
56. EudraCT-European Clinical Trials Database [database on the Internet] [cited 2012 February 27]. 
Available from: https://eudract.ema.europa.eu/eudract-web/index.faces. 
 
